

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## The Prevalence and Risk Factors of Epiretinal Membranes: Pooled Data from Population-Based Studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014644
Article Type:	Research
Date Submitted by the Author:	11-Oct-2016
Complete List of Authors:	Xiao, Wei; Sun Yat-Sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Chen, Xiaoyun; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Yan, William; University of Melbourne, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital Zhu, Zhuoting; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center He, Mingguang; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center; University of Melbourne, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital
<b>Primary Subject Heading</b>:	Ophthalmology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Epiretinal membranes, Prevalence, Risk factors, Meta-analysis, Population-based

SCHOLARONE™  
Manuscripts

only

1  
2 **The Prevalence and Risk Factors of Epiretinal Membranes: Pooled Data from**  
3  
4 **Population-Based Studies**  
5

6  
7 Wei Xiao<sup>1</sup>, Xiaoyun Chen<sup>1</sup>, William Yan<sup>2</sup>, Zhuoting Zhu<sup>1</sup>, Mingguang He<sup>1,2,\*</sup>  
8  
9

- 10 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun  
11  
12 Yat-sen University, Guangzhou, China  
13  
14 2. Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye  
15  
16 and Ear Hospital, Australia  
17  
18

19  
20 **\* Correspondence:**  
21

22 Mingguang He, M.D, Ph.D, FRANZCO  
23

24 Associate Director & Professor, Zhongshan Ophthalmic Center, Guangzhou 510060,  
25

26  
27 People's Republic of China  
28

29  
30 Tel: (86) 20 87331109; Fax: (86) 20 87331903  
31

32  
33 Email: mingguang.he@unimelb.edu.au  
34

35 **Running head:** The prevalence and risk factors of ERM  
36

37 **Financial support:** The Fundamental Research Funds of the State Key Laboratory  
38

39 of Ophthalmology (2016QN07), National Natural Science Foundation of China  
40

41 (81420108008) and Science and Technology Planning Project of Guangdong  
42

43 Province, China (2013B20400003). Dr. Mingguang He receives support from the  
44

45 University of Melbourne Research at Melbourne Accelerator Program Professorship.  
46

47 The Centre for Eye Research Australia receives operational infrastructural support  
48

49 from the Victorian government. Sponsor or funding organization had no role in the  
50

51 design or conduct of this research.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** The prevalence and risk estimates of epiretinal membranes (ERMs) are largely heterogeneous. The objective of this study was to aggregate the prevalence and risks of ERMs, and determine the possible causes of the varied estimates.

**Design:** Systematic review and meta-analysis.

**Data sources:** The search strategy was designed prospectively. We searched PubMed, Embase and Web of Science databases and reviewed reference lists of the literature selected.

**Study selection:** Surveys published in any language were included if they had a population-based design, and reported the prevalence of ERM from retinal photography with or without optical coherence tomography (OCT). Eligibility evaluation was conducted independently by two investigators.

**Data extraction:** The literature search generated 2,144 records, and thirteen population-based studies comprising 49,697 subjects were finally included.

**Results:** The pooled age-standardised prevalence estimates of earlier ERM (cellophane macular reflex, CMR), advanced ERM (preretinal macular fibrosis, PMF) and any ERM were 6.5% (95%CI: 4.2 to 8.9), 2.6% (95%CI: 1.8 to 3.4), and 9.1% (95%CI: 6.0 to 12.2), respectively. In the subgroup analysis, race and photography modality contributed to the variation in the prevalence estimates of PMF, while the WHO regions and image reading methods were associated with the varied prevalence of CMR and any ERM. Meta-analysis showed that only greater age and female significantly conferred a higher risk of ERMs.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Conclusions:** Our findings suggest that ERMs are relatively common among aged population. Race, image taking and reading methodology may play important roles in influencing the large variability of ERM prevalence estimates.

**Keywords:** Epiretinal membranes, Prevalence, Risk factors, Meta-analysis, Population-based

For peer review only

## Strengths and limitations of this study

- This study is the first systematic review and meta-analysis that pools the age-standardised prevalence of epiretinal membrane (ERM) from population-based studies.
- The investigators strictly adhered to the guidelines for systematic review and meta-analysis. All included surveys were of desirable quality and large-scale.
- We aggregated not only the prevalence of ERM but also its subtype estimates (CMR and PMF).
- Lack of studies from the African and European continents makes it difficult to project ERM prevalence estimates worldwide.
- We are unable to aggregate the data on the relationship between ERM prevalence and visual acuity impairment due to lack of studies on their association.

## INTRODUCTION

Epiretinal membranes (ERMs) are common retinal conditions that can impair visual acuity in old persons. ERMs may occur without any antecedent ocular conditions or surgical procedures, termed idiopathic or primary ERM. Those associated with other eye diseases (e.g. retinal vascular occlusion, diabetic retinopathy), trauma or surgery are referred to as secondary ERMs. Under ophthalmoscopy, earlier stage ERMs present as increases of the light reflex from the retina inner surface, which is called cellophane macular reflex (CMR). As the membrane progresses, it can contract and create superficial retinal folds. Massive folds make the retinae appear with gray linear reflexes, which are termed preretinal macular fibrosis (PMF). For most cases at the advanced stage, fibrotic membranes generate tangential traction on the macula, causing macular oedema, metamorphopsias and central vision impairment<sup>1</sup>.

After the landmark study Beaver Dam Eye Study (BDES) reported the prevalence of ERM in 1994<sup>2</sup>, several large-scale population-based studies investigated the epidemics of ERMs in Singapore<sup>3 4</sup>, Japan<sup>5</sup>, Australia<sup>6 7</sup> and China<sup>8 9</sup>. Most of these surveys introduced retinal photography, and the same classification scheme for ERMs as that in BDES. However, considerable variation in ERM epidemiology across races and regions has been noted. For example, in the population-based Multi-Ethnic Study of Atherosclerosis (MESA)<sup>10</sup>, ERM was as prevalent as 39.0% in Chinese, 27.5% in Caucasian, 26.2% in Africans, and 29.3% in Hispanics. These estimates were much higher than those in the Handan Eye Study in North China (3.4%)<sup>8</sup>, the Blue Mountains Eye Study (BMES) in Australia (7%)<sup>7</sup>, and the Los Angeles Latino Eye

1  
2 Study in the US (19.9%)<sup>11</sup>. Reasons for such variability may be complex, but it has  
3  
4 been considered to be associated with the differences in study design, population  
5  
6 characteristics, as well as the definition of cases. Moreover, some studies did not  
7  
8 compute the age-standardised estimates of prevalence, making direct comparisons  
9  
10 between studies difficult.  
11  
12

13  
14  
15  
16  
17 Estimating the prevalence and risk of ERM is perhaps the first step to better clinical  
18  
19 management, and understanding the burden of this disease. Therefore, we  
20  
21 conducted the present analysis to synthesise data from population-based studies to  
22  
23 estimate the prevalence of ERMs, to identify underlying factors causing prevalence  
24  
25 variability as well as major risk factors for ERMs.  
26  
27  
28  
29  
30  
31

## 32 **METHODS**

33  
34  
35 In this study, we followed the preferred reporting items for systematic reviews and  
36  
37 meta-analyses (the PRISMA statement, see Supplementary Information)<sup>12</sup>.  
38  
39  
40  
41

### 42 **Search strategy and selection criteria**

43  
44  
45 The search strategy was designed prospectively. We searched all reports on  
46  
47 population-based studies for the prevalence of ERMs using PubMed, Embase and  
48  
49 Web of Science from inception to July 2016. All English language articles were  
50  
51 retrieved using pre-specified search terms. The search terms and strategies were  
52  
53 showed in detail in Supplementary information. The reference lists of all included  
54  
55 articles were reviewed, and the full texts of potentially related papers were examined.  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 We designed a set of inclusion and exclusion criteria for literature screening. Studies  
6  
7 included were those population-based surveys in which ERMs were diagnosed on the  
8  
9 basis of retinal color photography or a combination of optical coherence tomography  
10  
11 (OCT). Studies without population-based (e.g., hospital- or specific population-based)  
12  
13 design were excluded. Eligibility evaluation was conducted independently by two  
14  
15 investigators (W.X and X.Y.C) using pre-designed forms. Any disagreements were  
16  
17 resolved by consensus.  
18  
19  
20  
21

### 22 23 24 25 **Quality assessment and data extraction**

26  
27 There were no consensus guidelines on evaluating cross-sectional surveys, so we  
28  
29 adopted the quality assessment criteria by de Weerd et al<sup>13</sup> and Rogers S et al<sup>14</sup>. The  
30  
31 criteria were designed to cover the following four aspects (Supplementary): 1)  
32  
33 Representing the general population. To achieve this, studies should be undertaken  
34  
35 using population registries, inhabitants of a specific area, or people registered with a  
36  
37 general practice. 2) Appropriately recruiting the population. Recruitment was  
38  
39 considered appropriate if it was performed randomly or consecutively rather than for  
40  
41 convenience or from volunteers. 3) Adequate response rate (>70%). 4) Objective  
42  
43 documentation of the outcomes. That means documentation of ERMs by retinal  
44  
45 photography according to standardised protocols and graded according to standard  
46  
47 definitions. Fulfillment of 3 or 4 points was considered adequate quality. Quality of all  
48  
49 included studies was assessed independently by two investigators (W.X and X.Y.C)  
50  
51 using quality assessment forms based on the aforementioned criteria.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 For included studies, data were extracted independently by two reviewers on to a  
6  
7 Microsoft Excel spreadsheet (XP professional edition; Microsoft, Redmond,  
8  
9 Washington, USA). Discrepancies were resolved by consensus. We extracted the  
10  
11 following data from each study: country, year, sample size, age range, race/ethnicity,  
12  
13 examination methods, crude prevalence of ERM and odds ratios (ORs) of risk factors.  
14  
15 Our key outcomes of interest were the prevalence and risk factors of ERM.  
16  
17  
18  
19  
20  
21

## 22 **Data synthesis and statistical analysis**

23  
24 Study-specific and pooled-data estimates of the prevalence of any ERM, CMR and  
25  
26 PMF were directly age-standardised to WHO World Standard age-structure<sup>15</sup>. A  
27  
28 random effect model was adopted to calculate pooled prevalence and odds ratios  
29  
30 (ORs) for the risk of ERM. Statistical analysis was performed with STATA software  
31  
32 (version 13.0, StataCorp LP, TX, USA). The  $I^2$  statistic was used to estimate  
33  
34 heterogeneity in pooled studies, and to further explore potential sources of  
35  
36 heterogeneity by subgroup analysis.  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **RESULTS**

46  
47 Figure 1 exhibits the results of the search strategy. The systematic searches yielded  
48  
49 2,144 records. After removing 906 duplications, 1,238 studies were screened through  
50  
51 titles and abstracts. Among them, we ruled out 1,186 irrelevant articles and reviewed  
52  
53 the left 52 studies in full text. Finally, we identified 13 studies<sup>2 3 5-11 16-18</sup> that were  
54  
55 eligible for inclusion (Table 1). Across the 13 studies, sample sizes ranged from  
56  
57  
58  
59  
60

1  
2 1,543<sup>5</sup> to 6,565<sup>8</sup>, including 49,697 individuals at risk of ERMs. Two studies (Funagata  
3  
4 and Hisayama) scored 3 points in the quality assessment owing to their relatively low  
5  
6 response rate, while the others all scored 4 points (see Supplementary Information).  
7  
8  
9 The Beixinjing Study<sup>18</sup> reported specifically on the prevalence of primary (idiopathic)  
10  
11 ERM, whereas the other 12 study documented the prevalence of any ERM (i.e. both  
12  
13 idiopathic and secondary ERM). Geographically, the WHO regions of Western Pacific  
14  
15 Region and the Americas were heavily represented, with all the 13 studies done in  
16  
17 these two regions. No studies had been done in the European, Africa, South-East  
18  
19 Asian or Eastern Mediterranean regions. Of these 13 studies, 12 studies (all except  
20  
21 Funagata<sup>5</sup>) assessed ERM using both eyes of each participant; 9 studies performed  
22  
23 photography after pharmacologic mydriasis. The methods of photography varied  
24  
25 between studies, with 4 studies using stereo-photographing (vs. 9 using non-stereo  
26  
27 photography), 4 studies using 30-degree camera (vs. 9 using 45-degree camera) and  
28  
29 6 using film photography (vs. 7 using digital photography). Retinal images were  
30  
31 graded at the reading centres at the University of Wisconsin-Madison (3 studies), the  
32  
33 University of Sydney (7 studies) or by independent ophthalmologists/trained graders  
34  
35 (4 studies). Characteristics of the included studies are summarised in Table 1.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Analyses of the 12 studies concerning any ERM (except the Beixinjing Study  
48  
49 exclusively on idiopathic ERM) showed that the overall age-standardised prevalence  
50  
51 of CMR was 6.5% (95% CI 4.2-8.9), PMF was 2.6% (95% CI 1.8-3.4), and any ERM  
52  
53 was 9.1% (95% CI 6.0-12.2) (Table 2). Specific to primary ERM, the pooled  
54  
55 prevalence of CMR, PMF and any primary ERM were 7.1% (95%CI 3.3-10.8), 2.0%  
56  
57  
58  
59  
60

1  
2 (95%CI 1.3-2.8) and 9.2% (95%CI 4.7-13.8), respectively. Six studies reported the  
3  
4 prevalence of secondary ERM, and all explicitly defined the population at-risk as  
5  
6 those with other ocular conditions (e.g. retinal vascular disease, retinal detachment)  
7  
8 and cataract surgery. The aggregated data showed the prevalence of secondary  
9  
10 CMR, PMF and any ERM were 11.4% (95%CI 4.4-18.5), 5.1% (95%CI 3.5-6.6) and  
11  
12 16.6% (95%CI 9.7-23.6), respectively.  
13  
14  
15  
16  
17  
18  
19

20 The age-standardised prevalence of ERMs by subgroups of interest was shown in  
21  
22 Table 3. The aggregated prevalence of any ERM varied according to the WHO  
23  
24 regions, different image acquisition and grading method. Three studies from the  
25  
26 Americas in which retinal images were also graded by the reading centre at the  
27  
28 University of Wisconsin-Madison<sup>2 10 11</sup> documented a much higher prevalence (14.4%)  
29  
30 than those from Western Pacific region (8.5%). Of note, this trend was attributed to  
31  
32 the increased prevalence of CMR in the Americas (14.3% vs. 4.0% in Western Pacific  
33  
34 region). For the more advance stage of CMR, studies in which film photography was  
35  
36 used (1.5%) synthesised a lower prevalence PMF than that used digital photography  
37  
38 (3.1%). PMF was slightly more prevalent in Asians (3.6%) than in Caucasians (2.5%).  
39  
40 There were two studies from China introduced OCT to confirm ERM<sup>8 9</sup>. Intriguingly,  
41  
42 studies with a combination of OCT demonstrated lower prevalence in both CMR (3.4%  
43  
44 vs. 7.2% without OCT) and PMF (1.8% vs. 2.8% without OCT).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 As expected, individuals with greater age were more likely to have any ERM  
56  
57 (OR=1.19 per year increase, 95%CI 1.13-1.26). Compared to males, females had a  
58  
59  
60

1  
2 higher risk of ERM (OR=1.34, 95%CI 1.17-1.53). Smokers had an unexpected lower  
3  
4 risk of ERM compared to non-smokers (OR=0.67, 95%CI 0.58-0.78). Other factors  
5  
6 analysed, including myopia, hyperopia, hypertension, diabetes, alcohol intake, early  
7  
8 age-related macular degeneration, body mass index and hyperlipidemia, were not  
9  
10 associated with the risk of any ERM (Table 4).  
11  
12  
13

## 14 15 16 17 **DISCUSSION**

18  
19 This study provides estimates for the prevalence of ERMs and its two stages using  
20  
21 data from most appropriate population-based studies in the literature. Using data from  
22  
23 13 studies with 49,697 participants, we estimated the age-standardised prevalence of  
24  
25 any ERM to be as high as 9.1%, with CMR and PMF as 6.5% and 2.6%, respectively.  
26  
27  
28 Race, retinal image taking and grading method were responsible for the variation of  
29  
30 the prevalence estimates. Of the risk factors analysed, greater age and female sex  
31  
32 were significantly associated with higher risk of ERMs.  
33  
34  
35  
36  
37  
38  
39

40 The prevalence of ERM has been documented over the last 30 years in several  
41  
42 population-based surveys. However, these estimates have varied considerably  
43  
44 across studies. For example, the prevalence of any ERM has been estimated to be  
45  
46 35.7% in Latinos aged 70 to 79 years<sup>11</sup>, while among Japanese of the same age it  
47  
48 has been reported to be 6.8%<sup>17</sup>. There is a need to synthesise the existing data to  
49  
50 form an age-standardised estimate of this prevalence and to explore possible sources  
51  
52 of heterogeneity. In this review, we identified 13 eligible studies with favorable quality,  
53  
54  
55 but they were largely conducted in Pacific Rim countries (the USA, Australia, Japan,  
56  
57  
58  
59  
60

1  
2 Singapore and China). Further study is warranted in European and African regions to  
3  
4 generate an accurate projection of worldwide ERM prevalence, and as such it falls  
5  
6 beyond the scope of this review.  
7  
8

9  
10 Previously, ERM susceptibility has been reported to vary between ethnic groups.

11  
12 MESA<sup>10</sup> was the only study that directly compared the racial and ethnic differences of  
13  
14 ERM prevalence within the same cohort. It reported a significantly higher prevalence  
15  
16 rate for Chinese ethnicity (39.0%), followed by Hispanic (29.3%), Caucasian (27.5%),  
17  
18 and African (26.2%) ethnicity. However, the sample sizes of each ethnic group were  
19  
20 relatively small, particularly in the Chinese subgroup (n=724). However, our data  
21  
22 found ethnicity to be less likely associated with ERM prevalence disparities. Our  
23  
24 pooled data showed the prevalence difference between Asians and Caucasians for  
25  
26 CMR and any ERM was negligible, indicating that race/ethnicity may have a limited  
27  
28 role in ERM prevalence.  
29  
30  
31  
32  
33  
34  
35  
36  
37

38  
39 Our review shows that the differences in ERM prevalence between studies may be  
40  
41 partly attributed to their methodological characteristics. Although all included studies  
42  
43 consistently adopted the same classification scheme for ERM as that in the Beaver  
44  
45 Dam Eye Study<sup>2</sup>, their retinal images were graded in different fashions: 3 studies  
46  
47 were read by the grading centre of the UW-Madison in the US, 6 at the grading centre  
48  
49 at the University of Sydney, and the others graded by ophthalmologists or  
50  
51 independently trained graders. In our subgroup analysis, three studies graded at the  
52  
53 reading centre at UW-Madison pooled an extremely high prevalence of CMR and any  
54  
55  
56  
57  
58  
59  
60

1  
2 ERM (14.3% and 14.4%, respectively). Due to all three studies from the Americas,  
3  
4 differences in image reading patterns directly led to the regional differences in CMR  
5  
6 and any ERM prevalence estimates. Taken account of the minimal difference in the  
7  
8 synthesised PMF prevalence across reading centres, we could speculate that the  
9  
10 substantial differences in estimated overall ERM prevalence originated from the  
11  
12 systematic differences in grading CMR from retinal images. Accordingly, there is  
13  
14 insufficient evidence to conclude whether the regional difference in ERM prevalence  
15  
16 is attributable to the difference in geographical location *per se* or to the grading  
17  
18 methodology. To address this issue, universal criteria for grading CMR and  
19  
20 differentiation from normal fundus manifestations may need to be further  
21  
22 standardised.  
23  
24  
25  
26  
27  
28  
29  
30

31 Interestingly, for more advanced stages of ERM, the pooled prevalence of PMF from  
32  
33 different reading centres and regions were quite similar, but this prevalence was more  
34  
35 likely to be affected by race and photography modality (film vs. digital). Asians had a  
36  
37 slightly higher prevalence of PMF (3.6% vs. 2.0% in Caucasians). Furthermore, digital  
38  
39 photography seemed to be better in detection of PMF compared to film photography.  
40  
41  
42  
43  
44  
45

46 Optical coherence tomography (OCT) has been applied as the gold standard in  
47  
48 diagnosing vitreoretinal interface diseases in recent epidemiological studies<sup>19-21</sup>. An  
49  
50 unexpected finding to comment on was that two studies using OCT produced much  
51  
52 lower prevalence rates of CMR, PMF or any ERM compared to the others without it.  
53  
54  
55 In clinical practice, OCT was superior to retinal photography in screening epiretinal  
56  
57  
58  
59  
60

1  
2 irregularities<sup>22</sup> and detecting subtle ERMs among special cases, such as those with  
3  
4 uveitis<sup>23</sup>. It follows that theoretically; studies using both photography and OCT should  
5  
6 detect more persons with ERMs. A hypothesis explaining this apparent contradiction  
7  
8 may be that OCT may exclude ERM suspects based on color retinal images. It  
9  
10 follows that further research is needed to assess the performance and  
11  
12 cost-effectiveness of OCT in diagnosing ERMs prior to its adoption as the  
13  
14 gold-standard test for epidemiological studies across the board.  
15  
16  
17  
18  
19  
20  
21

22 For pooled risk estimates, our data showed that only the associations between age  
23  
24 and sex, and the risk of any ERM were significant. Older and female individuals had  
25  
26 higher risk of ERM from the meta-analysis (OR=1.19 and 1.34, respectively). Owing  
27  
28 to the clear increase in the prevalence of ERMs with increasing age of the population,  
29  
30 ERM needs to be considered in a similar vein as age-related macular degeneration, a  
31  
32 condition that significantly affects an aging population. In terms of systemic and  
33  
34 ophthalmic risk factors, no significant association was found between ERM and  
35  
36 diabetes, hypertension, hyperlipidemia, BMI, myopia and early AMD.  
37  
38  
39  
40  
41  
42  
43  
44

45 Cigarette smoking, an important public health problem, is a well-documented risk  
46  
47 factor for several eye diseases, including age-related macular degeneration<sup>24</sup> and  
48  
49 thyroid-associated ophthalmopathy<sup>25</sup>. However, smoking can also serve as a  
50  
51 protective factor against the development of pterygium<sup>26</sup>. Although our analysis found  
52  
53 a negative association of ERM and smoking, this may be explained by a survival bias  
54  
55  
56  
57  
58  
59  
60



1  
2 among smokers that cannot be excluded from cross-sectional analysis, and should  
3  
4 not discredit the importance of smoking cessation across populations.  
5  
6  
7  
8

9  
10 Strengths of the present study include the large sample size, specific and inclusive  
11  
12 nature of criteria for population-based studies, and the inclusion of ERM subtype  
13  
14 estimates (CMR and PMF). The pooled data provide a precise estimate of the ERM  
15  
16 age-standard prevalence in the American and Asian-pacific population. However, our  
17  
18 study contains several limitations as well: firstly the lack of studies from the African  
19  
20 and European continents makes it difficult to project these prevalence estimates  
21  
22 worldwide. Second, samples from different study designs had considerably different  
23  
24 inclusion criteria, participant selection processes, and study protocols. For example,  
25  
26 sample populations were found to have considerably differences in proportions of  
27  
28 subjects with cardiovascular disease or diabetes complications<sup>9-11</sup>. Third, although  
29  
30 ERM, especially PMF, can cause moderate to severe visual impairment and  
31  
32 metamorphopsias<sup>4</sup>, most studies did not quantitatively analysed the association  
33  
34 between ERM and visual acuity. In this study, we are consequently unable to  
35  
36 aggregate the data on their relationship.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 **CONCLUSIONS**

48  
49 In conclusion, our current study provides the first estimate of ERM and its different  
50  
51 subtypes based on a pooled analysis of more than 40,000 participants from 13  
52  
53 studies in the US and the Western Pacific region. Our study shows that 9.1% of  
54  
55 general population had some form of ERM, 6.5% had CMR, and that 2.6% had the  
56  
57  
58  
59  
60

1  
2 advanced form of PMF. These data suggest that ERMs have the potential to be a  
3  
4 major cause of visual impairment. In some specific regions, such as Europe and  
5  
6 Africa, robust evidence for the prevalence and risk of ERM is absent. To address  
7  
8 these gaps in the evidence, high quality epidemiological research is needed that  
9  
10 focuses specifically on these countries using standardised measures of diseases.  
11  
12 Finally, we confirmed the significance and impact of two major risk factors, being age  
13  
14 and sex, on the risk of any form of ERM.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Bu SC, Kuijjer R, Li XR, Hooymans JM, Los LI. Idiopathic epiretinal membrane. *Retina* 2014;34(12):2317-35.
2. Klein R, Klein BE, Wang Q, Moss SE. The epidemiology of epiretinal membranes. *Trans Am Ophthalmol Soc* 1994;92:403-25.
3. Koh V, Cheung CY, Wong WL, Cheung CM, Wang JJ, Mitchell P, et al. Prevalence and risk factors of epiretinal membrane in Asian Indians. *Invest Ophthalmol Vis Sci* 2012;53(2):1018-22.
4. Cheung N, Tan SP, Lee SY, Cheung GC, Tan G, Kumar N, et al. Prevalence and risk factors for epiretinal membrane: the Singapore Epidemiology of Eye Disease study. *Br J Ophthalmol* 2016.
5. Kawasaki R, Wang JJ, Sato H, Mitchell P, Kato T, Kawata S, et al. Prevalence and associations of epiretinal membranes in an adult Japanese population: the Funagata study. *Eye (Lond)* 2009;23(5):1045-51.
6. McCarty DJ, Mukesh BN, Chikani V, Wang JJ, Mitchell P, Taylor HR, et al. Prevalence and associations of epiretinal membranes in the visual impairment project. *Am J Ophthalmol* 2005;140(2):288-94.
7. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. *Ophthalmology* 1997;104(6):1033-40.
8. Duan XR, Liang YB, Friedman DS, Sun LP, Wei WB, Wang JJ, et al. Prevalence and associations of epiretinal membranes in a rural Chinese adult population: the Handan Eye Study. *Invest Ophthalmol Vis Sci* 2009;50(5):2018-23.
9. Ye H, Zhang Q, Liu X, Cai X, Yu W, Yu S, et al. Prevalence and associations of epiretinal membrane in an elderly urban Chinese population in China: the Jiangning Eye Study. *Br J Ophthalmol* 2015;99(12):1594-7.
10. Ng CH, Cheung N, Wang JJ, Islam AF, Kawasaki R, Meuer SM, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population. *Ophthalmology* 2011;118(4):694-9.
11. Fraser-Bell S, Ying-Lai M, Klein R, Varma R. Prevalence and associations of epiretinal membranes in latinos: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2004;45(6):1732-6.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.
13. de Weerd M, Greving JP, de Jong AW, Buskens E, Bots ML. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis. *Stroke* 2009;40(4):1105-13.
14. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. *Ophthalmology* 2010;117(2):313-9 e1.
15. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age standardization of rates: a new who standard. Geneva: World Health Organization. Available at: <http://www.who.int/healthinfo/paper31.pdf>. 2001:(Accessed: 20th June 2015).

- 1 16. Kawasaki R, Wang JJ, Mitchell P, Aung T, Saw SM, Wong TY. Racial difference in the  
2 prevalence of epiretinal membrane between Caucasians and Asians. *Br J Ophthalmol*  
3 2008;92(10):1320-4.
- 4 17. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Iida M, Ishibashi T, et al. Prevalence  
5 and risk factors for epiretinal membranes in a Japanese population: the Hisayama  
6 study. *Graefes Arch Clin Exp Ophthalmol* 2003;241(8):642-6.
- 7 18. Zhu XF, Peng JJ, Zou HD, Fu J, Wang WW, Xu X, et al. Prevalence and risk factors of  
8 idiopathic epiretinal membranes in Beixinjing blocks, Shanghai, China. *PLoS One*  
9 2012;7(12):e51445.
- 10 19. Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity  
11 index as a measure of vascular status of the choroid: Measurements in healthy eyes  
12 from a population-based study. *Sci Rep* 2016;6:21090.
- 13 20. Meuer SM, Myers CE, Klein BE, Swift MK, Huang Y, Gangaputra S, et al. The  
14 epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain  
15 optical coherence tomography: the beaver dam eye study. *Ophthalmology*  
16 2015;122(4):787-95.
- 17 21. Patel PJ, Foster PJ, Grossi CM, Keane PA, Ko F, Lotery A, et al. Spectral-Domain  
18 Optical Coherence Tomography Imaging in 67 321 Adults: Associations with  
19 Macular Thickness in the UK Biobank Study. *Ophthalmology* 2016;123(4):829-40.
- 20 22. Ouyang Y, Heussen FM, Keane PA, Sadda SR, Walsh AC. The retinal disease screening  
21 study: prospective comparison of nonmydriatic fundus photography and optical  
22 coherence tomography for detection of retinal irregularities. *Invest Ophthalmol Vis*  
23 *Sci* 2013;54(2):1460-8.
- 24 23. Nicholson BP, Zhou M, Rostamizadeh M, Mehta P, Agron E, Wong W, et al.  
25 Epidemiology of epiretinal membrane in a large cohort of patients with uveitis.  
26 *Ophthalmology* 2014;121(12):2393-8.
- 27 24. Myers CE, Klein BE, Gangnon R, Sivakumaran TA, Iyengar SK, Klein R. Cigarette  
28 smoking and the natural history of age-related macular degeneration: the Beaver Dam  
29 Eye Study. *Ophthalmology* 2014;121(10):1949-55.
- 30 25. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves'  
31 ophthalmopathy and smoking. *Lancet* 1990;335(8700):1261-3.
- 32 26. Rong SS, Peng Y, Liang YB, Cao D, Jhanji V. Does cigarette smoking alter the risk of  
33 pterygium? A systematic review and meta-analysis. *Invest Ophthalmol Vis Sci*  
34 2014;55(10):6235-43.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

## Acknowledgments

This work was supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology (2016QN07), National Natural Science Foundation of China (81420108008) and Science and Technology Planning Project of Guangdong Province, China (2013B20400003).

## Author Contributions

Author MGH conceived and designed the study; Authors WX and XYC performed the literature search, study selection, data extraction and synthesis. Author WX prepared the draft manuscript; Authors WY, ZTZ and MGH were involved in the revision and final preparation of the manuscript.

## Competing financial interests

The Authors have no competing financial interests to report.

## Data Sharing Statement

No additional unpublished data are available

**Table 1.** Characteristics of included studies

Study	Country	Year	N(%male)	Age range	Race/Ethnicity	Eye examined	Pupil dilation	Fundus photography	Image grading	OCT used
BDES	USA	1987-88	4802	43-84	Caucasian	Both	Yes	30-degree; stereo; $\geq 3$ fields; film	Reading center at University of Wisconsin	No
Beixinjing*	China	2010-11	3326 (44.5)	50-98	Asian	Both	Yes	45-degree; non-stereo; 2 fields; digital	Ophthalmologists	No
BMES	Australia	1992-93	3490 (43.8)	$\geq 49$	Caucasian	Both	Yes	30-degree; stereo; 6 fields; film	Reading center at University of Sydney	No
Funagata	Japan	2000-02	1543 (43.4)	$\geq 35$	Asian	Right eye	No	45-degree; non-stereo; 1 field; film	Reading center at University of Sydney	No
HES	China	2006-07	6565 (46.7)	$\geq 30$	Asian	Both	Part of*	45-degree; non-stereo; 2 fields; digital	Ophthalmologists	Yes
Hisayama	Japan	1998	1765 (38.5)	$\geq 40$	Asian	Both	Yes	45-degree; non-stereo; 1 field; film	Ophthalmologists	No
Jiangning	China	2012-13	2005 (43.7)	$\geq 50$	Asian	Both	No	45-degree; non-stereo; $\geq 2$ fields; digital	Trained graders	Yes
LALES	USA	2000-03	5982 (42.0)	$\geq 40$	Hispanic	Both	Yes	30-degree; stereo, 3 fields; film	Reading center at University of Wisconsin	No
MESA	USA	2002-04	5960 (47.9)	45-84	White, Black; Asian; Hispanic	Both	No	45-degree; non-stereo; 2 fields; digital	Reading center at University of Wisconsin	No
SCES	Singapore	2009-11	3353	40-80	Asian	Both	Yes	45-degree; non-stereo; 2	Reading center at	No

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

								fields; digital	University of Sydney	
SiMES	Singapore	2004-06	3265 (48.1)	40-80	Asian	Both	Yes	45-degree; non-stereo; 2 fields; digital	Reading center at University of Sydney	No
SINDI	Singapore	2007-09	3328 (50.2)	40-80	Asian	Both	Yes	non-stereo; 2 fields; digital	Reading center at University of Sydney	No
VIP	Australia	1992-97	4313 (47.0)	≥40	Caucasian	Both	Yes	30-degree; stereo; 2 field; film	Reading center at University of Sydney	No

\* Data only available for primary ERMs.

For peer review only

**Table 2.** Age-standardised prevalence of epiretinal membrane by study

Study	Year	N at-risk	Crude prevalence (%)			Age-standardised prevalence (%; 95%CI)		
			CMR	PMF	Any ERM	CMR	PMF	Any ERM
<b>All ERM</b>								
BDES	1987-88	4802	-	-	-	4.8 (4.3-5.4)	1.7 (1.3-2.0)	6.4 (5.8-7.1)
BMES	1992-93	3490	4.8	2.7	7.0	3.8 (3.2-4.4)	1.7 (1.3-2.1)	5.5 (4.8-6.2)
Funagata	2000-02	1543	4.0	1.5	5.4	2.7 (1.9-3.4)	1.1 (0.6-1.5)	3.7 (2.8-4.6)
HES	2006-07	6565	2.2	0.7	3.4	2.3 (1.8-2.8)	0.6 (0.4-0.7)	3.5 (2.9-4.0)
Hisayama	1998	1765	3.2	0.9	4.0	2.2 (1.6-2.9)	0.5 (0.2-0.8)	2.8 (2.1-3.5)
Jiangning	2012-13	2005	5.0	3.4	8.4	4.5 (3.7-5.4)	3.1 (2.4-3.9)	7.6 (6.5-8.7)
LALES	2000-03	5982	16.3	2.2	18.5	16.6 (15.7-17.6)	2.5 (2.0-2.9)	19.0 (18.0-20.0)
MESA	2002-04	5960	25.1	3.8	28.9	21.5 (20.1-22.5)	3.0 (2.6-3.4)	24.5(23.4-25.6)
SIMES	2004-06	3265	5.8	5.9	11.8	4.7 (4.0-5.3)	4.6 (4.0-5.3)	9.3 (8.3-10.2)
SCES	2009-11	3353	-	-	-	7.0 (6.1-7.9)	7.5 (6.6-8.3)	13.0 (11.9-14.2)
SINDI	2007-09	3328	5.4	4.8	10.2	4.7 (4.0-5.3)	4.1 (3.4-4.7)	8.8 (7.9-9.7)
VIP	1992-97	4313	4.8	1.7	6.0	3.8 (3.3-4.4)	1.4 (1.1-1.8)	4.9 (4.4-5.5)
<b>Pooled estimates</b>	<b>NA</b>	<b>46371</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>6.5 (4.2-8.9)</b>	<b>2.6 (1.8-3.4)</b>	<b>9.1 (6.0-12.2)</b>
<b>Primary ERM</b>								



BDES	1987-88	4125	-	-	-	4.5 (3.9-5.1)	1.3 (1.0-1.6)	5.8 (5.1-6.5)
Beixinjing	2010-11	3326	0.6	0.6	1.0	0.6 (0.3-0.9)	0.4 (0.2-0.6)	1.0 (0.6-1.3)
HES	2006-07	6196	2.0	0.5	3.0	2.1 (1.6-2.6)	0.4 (0.3-0.6)	3.1 (2.6-3.7)
Jiangning	2012-13	1854	4.6	3.1	7.7	4.3 (3.4-5.2)	3.0 (2.2-3.7)	7.3 (6.1-8.4)
LALES	2000-03	5631	15.6	1.9	17.5	16.1 (15.2-17.1)	2.2 (1.8-2.6)	18.4 (17.3-19.4)
MESA	2002-04	4761	22.7	3.3	26.1	20.2 (19.1-21.3)	2.7 (2.3-3.1)	23.0 (21.7-24.1)
SIMES	2004-06	2734	5.1	4.5	9.5	4.5 (3.7-5.2)	3.8 (3.2-4.5)	8.3 (7.3-9.3)
SINDI	2007-09	2324	3.8	2.7	6.5	4.3 (3.4-5.2)	2.8 (2.1-3.5)	7.0 (5.9-8.2)
<b>Pooled estimates</b>	<b>NA</b>	<b>30951</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>7.1 (3.3-10.8)</b>	<b>2.0 (1.3-2.8)</b>	<b>9.2 (4.7-13.8)</b>
<b>Secondary ERM</b>								
HES	2006-07	269	7.1	3.7	12.3	6.7 (1.9-11.5)	3.7 (0-7.8)	11.1 (5.0-17.3)
Jiangning	2012-13	151	10.6	6.6	17.2	7.0 (3.4-10.7)	3.9 (1.2-6.6)	10.9 (6.6-15.2)
LALES	2000-03	345	27.0	7.5	34.5	19.8 (14.4-25.2)	6.1 (2.9-9.3)	25.9 (20.0-31.9)
MESA	2002-04	1199	34.3	5.8	40.1	25.1 (22.2-28.1)	3.4 (2.5-4.4)	28.6 (25.6-31.6)
SIMES	2004-06	531	9.8	13.6	23.4	5.3 (2.5-8.1)	7.1 (5.2-9.0)	12.4 (9.1-15.7)
SINDI	2007-09	1004	9.1	9.8	18.8	5.1 (3.6-6.5)	6.0 (4.2-7.8)	11.0 (8.8-13.3)
<b>Pooled estimates</b>	<b>NA</b>	<b>3499</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>11.4 (4.4-18.5)</b>	<b>5.1 (3.5-6.6)</b>	<b>16.6 (9.7-23.6)</b>

**Table 3.** Age-standardised prevalence of epiretinal membranes by subgroups of interest


	CMR			PMF			Any ERM		
	Studies (n)	Prevalence (%; 95%CI)	I <sup>2</sup> (%)	Studies (n)	Prevalence (%; 95%CI)	I <sup>2</sup> (%)	Studies (n)	Prevalence (%; 95%CI)	I <sup>2</sup> (%)
<b>Race/ethnicity</b>									
Caucasian	4	8.9 (4.6-13.2)	99.4	4	2.0 (1.4-2.7)	88.8	4	11.0 (5.9-16.1)	99.5
Asian	8	6.5 (4.6-8.5)	98.2	8	3.6 (2.2-4.9)	98.7	8	10.5 (7.2-13.8)	99.1
<b>WHO Regions</b>									
The Americas	3	14.3 (3.6-25.0)	99.8	3	2.4 (1.6-3.2)	91.6	3	14.4 (5.6-23.2)	99.7
Western Pacific	9	4.0 (3.1-4.9)	94.2	9	2.7 (1.7-3.7)	98.3	9	8.5 (4.7-8.4)	98.2
<b>Testing method</b>									
Photography only	10	7.2 (4.2-10.1)	99.5	10	2.8 (1.9-3.7)	97.8	10	9.1 (6.0-12.2)	99.3
Photography + OCT	2	3.4 (1.2-5.5)	94.8	2	1.8 (0-3.7)	97.6	2	5.5 (1.5-9.5)	97.7
<b>Photography</b>									
Film	6	5.6 (2.5-8.8)	99.3	6	1.5 (0.9-2.0)	92.2	6	7.0 (3.4-10.7)	99.4
Digital	6	7.4 (3.2-11.7)	99.5	6	3.8 (1.9-5.7)	99.0	6	10.0 (5.7-14.3)	99.3
<b>Image graded by</b>									
RC at UW–Madison <sup>#</sup>	3	14.3 (3.6-25.0)	99.8	3	2.4 (1.6-3.2)	91.6	3	14.4 (5.6-23.2)	99.7
RC at USYD <sup>##</sup>	6	4.4 (3.5-5.4)	92.3	6	3.4 (1.9-4.9)	98.1	6	7.5 (5.1-9.9)	98.1
Ophthalmologists or trained raters	3	3.0 (1.7-4.2)	90.9	3	2.6 (1.8-3.4)	98.1	3	4.6 (2.3-6.8)	96.4

<sup>#</sup>: Reading center at University of Wisconsin-Madison;

<sup>##</sup>: Reading center at University of Sydney.

**Table 4.** Pooled odds ratios for risk of any epiretinal membrane

Risk factors	Studies	OR (95%CI)	I <sup>2</sup> (%)
Age (per year)	5	<b>1.19 (1.13, 1.26)</b>	95.1
Sex (female)	6	<b>1.34 (1.17, 1.53)</b>	24.8
Myopia (present)	4	1.21 (0.67, 2.19)	88.9
Hyperopia (present)	3	1.23 (0.78, 1.94)	83.8
Hypertension (present)	6	1.04 (0.90, 1.20)	11.2
Diabetes (present)	6	1.13 (0.92, 1.38)	17.1
Smoking (present)	7	<b>0.67 (0.58, 0.78)</b>	0
Alcohol intake (present)	3	0.97 (0.75, 1.25)	0
Early AMD (present)	3	0.96 (0.63, 1.47)	60.7
BMI (per kg/m <sup>2</sup> )	5	0.99 (0.98, 1.01)	0
Hyperlipidemia (present)	4	1.05 (0.99, 1.11)	62.0



# The Prevalence and Risk Factors of Epiretinal Membranes: Pooled Data from Population-Based Studies

Wei Xiao, Xiaoyun Chen, William Yan, Zhuoting Zhu, Mingguang He

## Supplementary information

**Note.** Literature search strategy

### Terms

1. prevalence, epidemiology, epidemic\*, risk
2. epiretinal membrane\*; erm\*; ierm\*; cellophane macular reflex; preretinal macular fibrosis

### Search strategy

#### PubMed (up to July 11, 2016)

#1	prevalence Fields: Title/Abstract	459388
#2	epidemiology Fields: Title/Abstract	143403
#3	epidemic* Fields: Title/Abstract	80597
#4	risk Fields: Title/Abstract	1507737
#5	#1 OR #2 OR #3 OR #4	1973101
#6	epiretinal membrane* Fields: Title/Abstract	2259
#7	ERM Fields: Title/Abstract	3126
#8	iERM Fields: Title/Abstract	23
#9	cellophane macular reflex Fields: All fields	18
#10	preretinal macular fibrosis Fields: All fields	69
#11	#6 OR #7 OR #8 OR #9 OR #10	4935
#12	#5 AND #11	569

#### Embase (up to July 11, 2016)

#1	prevalence Fields: ti, ab	609473
#2	epidemiology Fields: ti, ab	144993
#3	epidemic* Fields: ti, ab	89089
#4	risk Fields: ti, ab	2059117
#5	#1 OR #2 OR #3 OR #4	2622649
#6	epiretinal membrane* Fields: ti, ab	2491
#7	ERM Fields: ti, ab	3555
#8	iERM Fields: ti, ab	22
#9	cellophane macular reflex Fields: All fields	18
#10	preretinal macular fibrosis Fields: All fields	75
#11	#6 OR #7 OR #8 OR #9 OR #10	5570
#12	#5 AND #11	619

#### Web of Science (All Databases, 1980 to Jun 20, 2015)

#### All languages, all document types

#1	TS = prevalence	684438
#2	TS = epidemiology	1440407
#3	TS=epidemic*	100419
#4	TS=risk	2386116
#5	#1 OR #2 OR #3 OR #4	3597103
#6	TS=epiretinal membrane*	3045
#7	TS=ERM	369
#8	TS=iERM	21
#9	TS=cellophane macular reflex	17
#10	TS=preretinal macular fibrosis	67
#11	#6 OR #7 OR #8 OR #9 OR #10	6344
#12	#5 AND #11	956

**Table S1.** Appraisal criteria for study methodology

Quality Criteria	Maximum score
1. Representing the general population	1
2. Appropriately recruiting the population	1
3. Adequate response rate (>70%)	1
4. Objective documentation of the outcomes	1

For peer review only

**Table S2.** Quality score of included studies

Study	Representing the general population	Appropriately recruiting the population	Adequate response rate (>70%)	Objective documentation of the outcomes	Total score
BDES	1	1	1	1	4
Beixinjing	1	1	1	1	4
BMES	1	1	1	1	4
Funagata	1	1	0	1	3
HES	1	1	1	1	4
Hisayama	1	1	0	1	3
Jiangning	1	1	1	1	4
LALES	1	1	1	1	4
MESA	1	1	1	1	4
SCES	1	1	1	1	4
SiMES	1	1	1	1	4
SINDI	1	1	1	1	4
VIP	1	1	1	1	4



# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not available
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6, Suppl. info
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	8

# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10, table2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	table 2-4
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-11, table3
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1, 19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

# BMJ Open

## The Prevalence and Risk Factors of Epiretinal Membranes: Pooled Data from Population-Based Studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014644.R1
Article Type:	Research
Date Submitted by the Author:	06-Jun-2017
Complete List of Authors:	Xiao, Wei; Sun Yat-Sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Chen, Xiaoyun; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Yan, William; University of Melbourne, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital Zhu, Zhuoting; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center He, Mingguang; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center; University of Melbourne, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital
<b>Primary Subject Heading</b>:	Ophthalmology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Epiretinal membranes, Prevalence, Risk factors, Meta-analysis, Population-based

SCHOLARONE™  
Manuscripts

only

1  
2 **The Prevalence and Risk Factors of Epiretinal Membranes: Pooled Data from**  
3  
4 **Population-Based Studies**  
5

6  
7 Wei Xiao<sup>1</sup>, Xiaoyun Chen<sup>1</sup>, William Yan<sup>2</sup>, Zhuoting Zhu<sup>1</sup>, Mingguang He<sup>1,2,\*</sup>  
8  
9

- 10 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun  
11  
12 Yat-sen University, Guangzhou, China  
13  
14 2. Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye  
15  
16 and Ear Hospital, Australia  
17  
18

19  
20 **\* Correspondence:**  
21

22 Mingguang He, M.D, Ph.D, FRANZCO  
23

24 Associate Director & Professor, Zhongshan Ophthalmic Center, Guangzhou 510060,  
25

26  
27 People's Republic of China  
28

29  
30 Tel: (86) 20 87331109; Fax: (86) 20 87331903  
31

32  
33 Email: mingguang.he@unimelb.edu.au  
34

35 **Running head:** The prevalence and risk factors of ERM  
36

37 **Financial support:** The Fundamental Research Funds of the State Key Laboratory  
38

39 of Ophthalmology (2016QN07), National Natural Science Foundation of China  
40

41 (81420108008) and Science and Technology Planning Project of Guangdong  
42

43 Province, China (2013B20400003). Dr. Mingguang He receives support from the  
44

45 University of Melbourne Research at Melbourne Accelerator Program Professorship.  
46

47 The Centre for Eye Research Australia receives operational infrastructural support  
48

49 from the Victorian government. Sponsor or funding organization had no role in the  
50

51 design or conduct of this research.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** This study was to aggregate the prevalence and risks of ERMs, and determine the possible causes of the varied estimates.

**Design:** Systematic review and meta-analysis.

**Data sources:** The search strategy was designed prospectively. We searched PubMed, Embase and Web of Science databases from inception to July 2016. Reference lists of the included literatures were reviewed as well.

**Study selection:** Surveys published in English language from any population were included if they had a population-based design, and reported the prevalence of ERM from retinal photography with or without optical coherence tomography (OCT). Eligibility and quality evaluation was conducted independently by two investigators.

**Data extraction:** The literature search generated 2,144 records, and thirteen population-based studies comprising 49,697 subjects were finally included. The prevalence of ERM, and the odds ratios of potential risk factors (age, sex, myopia, hypertension, etc.) were extracted.

**Results:** The pooled age-standardised prevalence estimates of earlier ERM (cellophane macular reflex, CMR), advanced ERM (preretinal macular fibrosis, PMF) and any ERM were 6.5% (95%CI: 4.2 to 8.9), 2.6% (95%CI: 1.8 to 3.4), and 9.1% (95%CI: 6.0 to 12.2), respectively. In the subgroup analysis, race and photography modality contributed to the variation in the prevalence estimates of PMF, while the WHO regions and image reading methods were associated with the varied prevalence of CMR and any ERM. Meta-analysis showed that only greater age and female significantly conferred a higher risk of ERMs.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Conclusions:** Our findings suggest that ERMs are relatively common among aged population. Race, image taking and reading methodology may play important roles in influencing the large variability of ERM prevalence estimates.

**Keywords:** Epiretinal membranes, Prevalence, Risk factors, Meta-analysis, Population-based

For peer review only

## Strengths and limitations of this study

- This study is the first systematic review and meta-analysis that pools the age-standardised prevalence of epiretinal membrane (ERM) from population-based studies.
- The investigators strictly adhered to the guidelines for systematic review and meta-analysis. All included surveys were of desirable quality and large-scale.
- We aggregated not only the prevalence of ERM but also its subtype estimates (CMR and PMF).
- Lack of studies from the African and European continents makes it difficult to project ERM prevalence estimates worldwide.
- We are unable to aggregate the data on the relationship between ERM prevalence and visual acuity impairment due to lack of studies on their association.
- We only included literatures in English for the analysis.

## INTRODUCTION

Epiretinal membranes (ERMs) are common retinal conditions that can impair visual acuity in old persons. ERMs may occur without any antecedent ocular conditions or surgical procedures, termed idiopathic or primary ERM. Those associated with other eye diseases (e.g. retinal vascular occlusion, diabetic retinopathy), trauma or surgery are referred to as secondary ERMs. Under ophthalmoscopy, earlier stage ERMs present as increases of the light reflex from the retina inner surface, which is called cellophane macular reflex (CMR). As the membrane progresses, it can contract and create superficial retinal folds. Massive folds make the retinae appear with gray linear reflexes, which are termed preretinal macular fibrosis (PMF). For most cases at the advanced stage, fibrotic membranes generate tangential traction on the macula, causing macular oedema, metamorphopsias and central vision impairment<sup>1</sup>.

After the landmark study Beaver Dam Eye Study (BDES) reported the prevalence of ERM in 1994<sup>2</sup>, several large-scale population-based studies investigated the epidemics of ERMs in Singapore<sup>3 4</sup>, Japan<sup>5</sup>, Australia<sup>6 7</sup> and China<sup>8 9</sup>. Most of these surveys introduced retinal photography, and the same classification scheme for ERMs as that in BDES. However, considerable variation in ERM epidemiology across races and regions has been noted. For example, in the population-based Multi-Ethnic Study of Atherosclerosis (MESA)<sup>10</sup>, ERM was as prevalent as 39.0% in Chinese, 27.5% in Caucasian, 26.2% in Africans, and 29.3% in Hispanics. These estimates were much higher than those in the Handan Eye Study in North China (3.4%)<sup>8</sup>, the Blue Mountains Eye Study (BMES) in Australia (7%)<sup>7</sup>, and the Los Angeles Latino Eye



1  
2 Study in the US (19.9%)<sup>11</sup>. Reasons for such variability may be complex, but it has  
3  
4 been considered to be associated with the differences in study design, population  
5  
6 characteristics, as well as the definition of cases. Moreover, some studies did not  
7  
8 compute the age-standardised estimates of prevalence, making direct comparisons  
9  
10 between studies difficult.  
11  
12

13  
14  
15  
16  
17 Estimating the prevalence and risk of ERM is perhaps the first step to better clinical  
18  
19 management, and understanding the burden of this disease. Therefore, we  
20  
21 conducted the present analysis to synthesise data from population-based studies to  
22  
23 estimate the prevalence of ERMs, to identify underlying factors causing prevalence  
24  
25 variability as well as major risk factors for ERMs.  
26  
27  
28  
29  
30  
31

## 32 **METHODS**

33  
34  
35 In this study, we followed the preferred reporting items for systematic reviews and  
36  
37 meta-analyses (the PRISMA statement<sup>12</sup>, see Supplementary Information).  
38  
39  
40  
41

### 42 **Search strategy and selection criteria**

43  
44  
45 The search strategy was designed prospectively. We searched all reports on  
46  
47 population-based studies for the prevalence of ERMs using PubMed, Embase and  
48  
49 Web of Science from inception to July 2016. All English language articles were  
50  
51 retrieved using pre-specified search terms. The search terms and strategies were  
52  
53 showed in detail in Supplementary information. The reference lists of all included  
54  
55 articles were reviewed, and the full texts of potentially related papers were examined.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 We designed a set of inclusion and exclusion criteria for literature screening. Studies  
6  
7 included were those population-based surveys in which ERMs were diagnosed on the  
8  
9 basis of retinal color photography with or without a combination of optical coherence  
10  
11 tomography (OCT). Studies without population-based (e.g., hospital- or specific  
12  
13 population-based) design were excluded. Eligibility evaluation was conducted  
14  
15 independently by two investigators (W.X and X.Y.C) using pre-designed forms. Any  
16  
17 disagreements were resolved by consensus.  
18  
19  
20  
21  
22  
23  
24

### 25 **Quality assessment and data extraction**

26  
27 There were no consensus guidelines on evaluating cross-sectional surveys, so we  
28  
29 adopted the quality assessment criteria by de Weerd et al<sup>13</sup> and Rogers S et al<sup>14</sup>. The  
30  
31 criteria covered the following four aspects (Supplementary Information): 1)  
32  
33 Representing the general population. To achieve this, studies should be undertaken  
34  
35 using population registries, inhabitants of a specific area, or people registered with a  
36  
37 general practice. 2) Appropriately recruiting the population. Recruitment was  
38  
39 considered appropriate if it was performed randomly or consecutively rather than for  
40  
41 convenience or from volunteers. 3) Adequate response rate (>70%). 4) Objective  
42  
43 documentation of the outcomes. That means documentation of ERMs by retinal  
44  
45 photography according to standardised protocols and graded according to standard  
46  
47 definitions. Fulfillment of 3 or 4 points was considered adequate quality. Quality of all  
48  
49 included studies was assessed independently by two investigators (W.X and X.Y.C)  
50  
51 using quality assessment forms based on the aforementioned criteria.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 For included studies, data were extracted independently by two reviewers (W.X and  
6  
7 X.Y.C) on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft,  
8  
9 Redmond, Washington, USA). Discrepancies were resolved by consensus. We  
10  
11 extracted the following data from each study: country, year, sample size, age range,  
12  
13 race/ethnicity, examination methods, crude prevalence, and odds ratios (ORs) of risk  
14  
15 factors (including age, gender, refractive error, hypertension, diabetes, smoking  
16  
17 status, alcohol intake, early AMD, body mass index and hyperlipidemia). Our key  
18  
19 outcomes of interest were the prevalence and risk factors of ERM.  
20  
21  
22  
23  
24  
25  
26

### 27 **Data synthesis and statistical analysis**

28  
29 Age-standardised prevalence of ERMs were calculated by projecting study-specific  
30  
31 estimate to the WHO World Standard age-structure<sup>15</sup>. A random effect model was  
32  
33 adopted to calculate pooled prevalence and odds ratios (ORs) for the risk of ERM.  
34  
35 The  $I^2$  statistic was used to estimate heterogeneity in pooled studies. Potential  
36  
37 sources of heterogeneity were explored by subgroup analysis. All statistical analysis  
38  
39 was performed with STATA software (version 13.0, StataCorp LP, TX, USA).  
40  
41  
42  
43  
44  
45  
46

## 47 **RESULTS**

48  
49 Figure 1 exhibits the procedure of literature searching and screening. The systematic  
50  
51 searches yielded 2,144 records. After removing 906 duplications, 1,238 studies were  
52  
53 screened through titles and abstracts. Among them, we ruled out 1,186 irrelevant  
54  
55 articles and reviewed the left 52 studies in full text. Finally, we identified 13 studies<sup>2 3</sup>  
56  
57  
58  
59  
60

1  
2 5-11 16-18 that were eligible for inclusion (Table 1). Across the 13 studies, sample sizes  
3  
4 ranged from 1,543<sup>5</sup> to 6,565<sup>8</sup>, including 49,697 individuals at risk of ERMs. Two  
5  
6 studies (Funagata and Hisayama) scored 3 points in the quality assessment owing to  
7  
8 their relatively low response rate (<70%), while the others all scored 4 points (see  
9  
10 Supplementary Information). The Beixinjing Study<sup>18</sup> reported specifically on the  
11  
12 prevalence of primary (idiopathic) ERM, whereas the other 12 study documented the  
13  
14 prevalence of any ERM (i.e. both primary and secondary ERM). Geographically, the  
15  
16 WHO regions of Western Pacific Region and the Americas were heavily represented,  
17  
18 with all 13 studies done in these two regions. In other words, no studies had been  
19  
20 done in the European, Africa, South-East Asian or Eastern Mediterranean regions. Of  
21  
22 these 13 studies, 12 studies (all except Funagata<sup>5</sup>) assessed ERM using both eyes of  
23  
24 each participant; 9 studies performed photography after pharmacologic mydriasis.  
25  
26 The methods of photography varied between studies, with 4 studies using  
27  
28 stereo-photography (vs. 9 using non-stereo photography), 4 studies using  
29  
30 30-degree camera (vs. 9 using 45-degree camera) and 6 using film photography (vs.  
31  
32 7 using digital photography). Retinal images were graded at the reading centres at  
33  
34 the University of Wisconsin-Madison (3 studies), at the University of Sydney (7  
35  
36 studies), or by independent ophthalmologists/trained graders (4 studies).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 Characteristics of the included studies are summarised in Table 1.

49  
50  
51  
52 Analyses of the 12 studies concerning any ERM (except the Beixinjing Study  
53  
54 exclusively on primary ERM) showed that the overall age-standardised prevalence of  
55  
56 CMR was 6.5% (95% CI 4.2-8.9), PMF was 2.6% (95% CI 1.8-3.4), and any ERM  
57  
58  
59  
60

1  
2 was 9.1% (95% CI 6.0-12.2) (Table 2). Specific to primary ERM, the pooled  
3  
4 prevalence of CMR, PMF and all primary ERM were 7.1% (95%CI 3.3-10.8), 2.0%  
5  
6 (95%CI 1.3-2.8) and 9.2% (95%CI 4.7-13.8), respectively. Six studies reported the  
7  
8 prevalence of secondary ERM, and all explicitly defined the population at-risk as  
9  
10 those with other ocular conditions (e.g. retinal vascular disease, retinal detachment)  
11  
12 or cataract surgery. The aggregated data showed the prevalence of secondary CMR,  
13  
14 PMF and any ERM were 11.4% (95%CI 4.4-18.5), 5.1% (95%CI 3.5-6.6) and 16.6%  
15  
16 (95%CI 9.7-23.6), respectively.  
17  
18  
19  
20  
21  
22  
23  
24

25 The age-standardised prevalence of ERMs by subgroups of interest was shown in  
26  
27 Table 3. The aggregated prevalence of any ERM varied according to the WHO  
28  
29 regions, different image acquisition and grading method. Three studies from the  
30  
31 Americas, in which retinal images were also graded by the reading centre at the  
32  
33 University of Wisconsin-Madison<sup>2 10 11</sup>, documented a much higher prevalence  
34  
35 (14.4%) than those from Western Pacific region (8.5%). Of note, this trend was  
36  
37 potentially attributed to the extremely high prevalence of CMR in the Americas (14.3%  
38  
39 vs. 4.0% in Western Pacific region). For PMF, the advanced stage of ERM, studies  
40  
41 using film photography synthesised a much lower prevalence than that using digital  
42  
43 photography (1.5% vs. 3.1%). PMF was slightly more prevalent in Asians than in  
44  
45 Caucasians (3.6% vs. 2.5%). There were only two studies from China introduced  
46  
47 OCT to confirm ERM cases<sup>8 9</sup>. Intriguingly, studies with a combination of OCT  
48  
49 demonstrated lower prevalence in both CMR (3.4% vs. 7.2% without OCT) and PMF  
50  
51 (1.8% vs. 2.8% without OCT).  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 As expected, individuals with greater age were more likely to have any ERM  
6  
7 (OR=1.19 per year increase, 95%CI 1.13-1.26). Compared to males, females carried  
8  
9 higher risk of ERM (OR=1.34, 95%CI 1.17-1.53). Smokers had an unexpected lower  
10  
11 risk of ERM compared to non-smokers (OR=0.67, 95%CI 0.58-0.78). Other factors  
12  
13 analysed, including myopia, hyperopia, hypertension, diabetes, alcohol intake, early  
14  
15 age-related macular degeneration, body mass index and hyperlipidemia, were not  
16  
17 associated with the risk of any ERM (Table 4).  
18  
19  
20  
21  
22  
23

## 24 **DISCUSSION**

25  
26  
27 This study provides estimates for the prevalence of ERMs and its two stages using  
28  
29 data from most appropriate population-based studies in the literature. Using data from  
30  
31 13 studies with 49,697 participants, we estimated the age-standardised prevalence of  
32  
33 any ERM (both primary and secondary) to be as high as 9.1%, with CMR and PMF as  
34  
35 6.5% and 2.6%, respectively. Race, retinal image taking and grading method were  
36  
37 responsible for the variation of the prevalence estimates across studies. Among the  
38  
39 factors analysed, greater age and female sex were significantly associated with  
40  
41 higher risk of developing ERMs.  
42  
43  
44  
45  
46  
47  
48  
49

50 The prevalence of ERM has been documented over the last 30 years in several  
51  
52 population-based surveys. However, these estimates have varied considerably  
53  
54 across studies. For example, the prevalence of any ERM has been estimated to be  
55  
56 35.7% in Latinos aged 70 to 79 years<sup>11</sup>, which was five-fold more prevalent than that  
57  
58  
59  
60

1  
2 in the same age Japanese (6.8%)<sup>17</sup>. To form an age-standardised estimate of ERM  
3 prevalence, and further to explore possible sources of heterogeneity, we conducted  
4 this study to synthesise the best available data. In this review, we identified 13 eligible  
5 studies with favorable quality, but they were predominantly carried out in Pacific Rim  
6 countries (the USA, Australia, Japan, Singapore and China). Further study is  
7 warranted in European and African regions so that we can generate the global  
8 prevalence, and magnitude of this disease.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Previously, ERM susceptibility has been reported to vary between ethnic groups.  
23 MESA<sup>10</sup> was the only study that directly compared the racial and ethnic differences of  
24 ERM prevalence within the same cohort. It reported a significantly higher prevalence  
25 rate for Chinese ethnicity (39.0%), followed by Hispanic (29.3%), Caucasian (27.5%),  
26 and African (26.2%) ethnicity. However, the sample sizes of each ethnic group were  
27 relatively small, particularly in the Chinese subgroup (n=724). However, our  
28 aggregated data of large sample size showed that ethnicity was less likely to be  
29 associated with ERM prevalence disparities. The prevalence difference between  
30 Asians and Caucasians for CMR and any ERM was negligible, indicating that  
31 race/ethnicity may have a limited role in ERM prevalence.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Our review shows that the variations in ERM prevalence between studies may be  
52 partly attributed to their methodological characteristics. In terms of image grading  
53 protocol, although all included studies consistently adopted the same classification  
54  
55  
56  
57  
58  
59  
60

1  
2 scheme as that in the Beaver Dam Eye Study<sup>2</sup>, retinal images were graded in  
3  
4 different fashions: 3 studies were read by the grading centre of the UW-Madison in  
5  
6 the US, 6 at the grading centre at the University of Sydney, and the others graded by  
7  
8 ophthalmologists or independently trained graders. In our subgroup analysis, three  
9  
10 studies graded at the reading centre at UW-Madison pooled an extremely high  
11  
12 prevalence of CMR and any ERM (14.3% and 14.4%, respectively). Due to all three  
13  
14 studies from the Americas, differences in image reading patterns directly led to the  
15  
16 regional differences in CMR and any ERM prevalence estimates. Taken account of  
17  
18 the minimal difference in the synthesised PMF prevalence across reading centres, we  
19  
20 could speculate that the substantial differences in estimated overall ERM prevalence  
21  
22 originated from the systematic differences in grading CMR from retinal images.  
23  
24 Accordingly, there is insufficient evidence to conclude whether the regional difference  
25  
26 in ERM prevalence is attributable to the difference in geographical location *per se* or  
27  
28 to the grading methodology. To address this issue, universal criteria for grading CMR  
29  
30 and differentiation from normal fundus manifestations may need to be further  
31  
32 standardised.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Interestingly, unlike CMR and any ERM, the pooled prevalence of PMF across  
44  
45 regions were quite similar, but this prevalence was more likely to be affected by race  
46  
47 and photography modality (film vs. digital). Asians had a slightly higher prevalence of  
48  
49 PMF (3.6% vs. 2.0% in Caucasians), and digital photography seemed to detect more  
50  
51 PMF cases than film photography (3.8% vs. 1.5%).  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Optical coherence tomography (OCT) has been applied as the “gold standard” in diagnosing vitreoretinal interface diseases in recent epidemiological studies<sup>19-21</sup>. In clinical practice, OCT was superior to retinal photography in screening epiretinal irregularities<sup>22</sup> and detecting subtle ERMs among special cases, such as those with uveitis<sup>23</sup>. It follows that theoretically; studies using both photography and OCT should detect more persons with ERMs. However, we unexpectedly found that two studies using OCT produced much lower prevalence rates of CMR, PMF and any ERM than the others without using it. A hypothesis explaining this apparent contradiction might be that OCT may exclude ERM suspects based on color retinal images. For example, OCT is capable of differentiating ERM from posterior vitreous detachment (PVD), another condition which frequently affect the elderly and resemble CMR on colour retinal images. Further research is needed to assess the performance and cost-effectiveness of OCT in diagnosing ERMs prior to its adoption as the gold-standard test for epidemiological studies across the board.

For pooled risk estimates, our data showed that only age and sex were significantly associated the risk of any ERMs. Older and female individuals had higher risk of ERM from the meta-analysis (OR=1.19 and 1.34, respectively). With increasing age of the global population, ERM needs to be considered in a similar vein as age-related macular degeneration, a condition that significantly affects the aging population. In terms of systemic and ophthalmic risk factors, no significant association was found between ERM and diabetes, hypertension, hyperlipidemia, BMI, myopia and early AMD.

1  
2  
3  
4 Cigarette smoking, on one hand, is a well-documented risk factor for several eye  
5  
6 diseases, including age-related macular degeneration<sup>24</sup> and thyroid-associated  
7  
8 ophthalmopathy<sup>25</sup>. On the other, smoking can also serve as a protective factor  
9  
10 against the development of pterygium<sup>26</sup>. Our analysis convinced a negative  
11  
12 association of ERM and smoking as well. This may be explained by a survival bias of  
13  
14 smokers that cannot be excluded from cross-sectional analysis. So these findings  
15  
16 should not discredit the importance of smoking cessation across populations.  
17  
18  
19  
20  
21  
22  
23

24 Strengths of the present study include the large sample size, specific and inclusive  
25  
26 nature of criteria for population-based studies, and the inclusion of ERM subtype  
27  
28 estimates (CMR and PMF). The pooled data provide a precise estimate of the ERM  
29  
30 age-standard prevalence in the American and Asian-pacific population. However, our  
31  
32 study contains several limitations as well. First, significant heterogeneity across  
33  
34 studies existed in most of our analysis. Although we found that retinal image  
35  
36 acquisition and grading methods might partly account for the heterogeneity, pooled  
37  
38 prevalence estimates in each subgroup were still heterogeneous (all  $I^2 > 50\%$ , Table  
39  
40 2 and 3). Second, the lack of studies from the African and European continents  
41  
42 makes it difficult to estimate the global prevalence and magnitude of ERM. Third,  
43  
44 samples from different study designs had considerably different inclusion criteria,  
45  
46 participant selection processes, and study protocols. For example, sample  
47  
48 populations were found to have considerably differences in proportions of subjects  
49  
50 with cardiovascular disease or diabetes complications<sup>9-11</sup>. Forth, although ERM,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 especially PMF, can cause moderate to severe visual impairment and  
3  
4 metamorphopsias<sup>4</sup>, most studies did not quantitatively analysed the association  
5  
6  
7 between ERM and visual acuity. In this study, we are consequently unable to  
8  
9  
10 aggregate the data on their relationship.

## 11 12 13 14 15 **CONCLUSIONS**

16  
17 In conclusion, our current study provides the first estimate of ERM and its different  
18  
19 subtypes based on a pooled analysis of more than 40,000 participants from 13  
20  
21 studies in the US and the Western Pacific region. Our study shows that 9.1% of  
22  
23 general population had some form of ERM, 6.5% had CMR, and 2.6% had the  
24  
25 advanced form of PMF. These data suggest that ERMs have the potential to be a  
26  
27 major cause of visual impairment. In some specific regions, such as Europe and  
28  
29 Africa, robust evidence for the prevalence and risk of ERM is absent. To address  
30  
31 these gaps in the evidence, high quality epidemiological research is needed that  
32  
33 focuses specifically on these countries using standardised measures of diseases.  
34  
35 Finally, we confirmed the significance and impact of two major factors, being age and  
36  
37 sex, on the risk of ERM.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Bu SC, Kuijter R, Li XR, Hooymans JM, Los LI. Idiopathic epiretinal membrane. *Retina* 2014;34(12):2317-35.
2. Klein R, Klein BE, Wang Q, Moss SE. The epidemiology of epiretinal membranes. *Trans Am Ophthalmol Soc* 1994;92:403-25.
3. Koh V, Cheung CY, Wong WL, Cheung CM, Wang JJ, Mitchell P, et al. Prevalence and risk factors of epiretinal membrane in Asian Indians. *Invest Ophthalmol Vis Sci* 2012;53(2):1018-22.
4. Cheung N, Tan SP, Lee SY, Cheung GC, Tan G, Kumar N, et al. Prevalence and risk factors for epiretinal membrane: the Singapore Epidemiology of Eye Disease study. *Br J Ophthalmol* 2016.
5. Kawasaki R, Wang JJ, Sato H, Mitchell P, Kato T, Kawata S, et al. Prevalence and associations of epiretinal membranes in an adult Japanese population: the Funagata study. *Eye (Lond)* 2009;23(5):1045-51.
6. McCarty DJ, Mukesh BN, Chikani V, Wang JJ, Mitchell P, Taylor HR, et al. Prevalence and associations of epiretinal membranes in the visual impairment project. *Am J Ophthalmol* 2005;140(2):288-94.
7. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. *Ophthalmology* 1997;104(6):1033-40.
8. Duan XR, Liang YB, Friedman DS, Sun LP, Wei WB, Wang JJ, et al. Prevalence and associations of epiretinal membranes in a rural Chinese adult population: the Handan Eye Study. *Invest Ophthalmol Vis Sci* 2009;50(5):2018-23.
9. Ye H, Zhang Q, Liu X, Cai X, Yu W, Yu S, et al. Prevalence and associations of epiretinal membrane in an elderly urban Chinese population in China: the Jiangning Eye Study. *Br J Ophthalmol* 2015;99(12):1594-7.
10. Ng CH, Cheung N, Wang JJ, Islam AF, Kawasaki R, Meuer SM, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population. *Ophthalmology* 2011;118(4):694-9.
11. Fraser-Bell S, Ying-Lai M, Klein R, Varma R. Prevalence and associations of epiretinal membranes in latinos: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2004;45(6):1732-6.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.
13. de Weerd M, Greving JP, de Jong AW, Buskens E, Bots ML. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis. *Stroke* 2009;40(4):1105-13.
14. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. *Ophthalmology* 2010;117(2):313-9 e1.
15. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age standardization of rates: a new who standard. Geneva: World Health Organization. Available at: <http://www.who.int/healthinfo/paper31.pdf>. 2001:(Accessed: 20th June 2015).

16. Kawasaki R, Wang JJ, Mitchell P, Aung T, Saw SM, Wong TY. Racial difference in the prevalence of epiretinal membrane between Caucasians and Asians. *Br J Ophthalmol* 2008;92(10):1320-4.
17. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Iida M, Ishibashi T, et al. Prevalence and risk factors for epiretinal membranes in a Japanese population: the Hisayama study. *Graefes Arch Clin Exp Ophthalmol* 2003;241(8):642-6.
18. Zhu XF, Peng JJ, Zou HD, Fu J, Wang WW, Xu X, et al. Prevalence and risk factors of idiopathic epiretinal membranes in Beixinjing blocks, Shanghai, China. *PLoS One* 2012;7(12):e51445.
19. Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. *Sci Rep* 2016;6:21090.
20. Meuer SM, Myers CE, Klein BE, Swift MK, Huang Y, Gangaputra S, et al. The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography: the beaver dam eye study. *Ophthalmology* 2015;122(4):787-95.
21. Patel PJ, Foster PJ, Grossi CM, Keane PA, Ko F, Lotery A, et al. Spectral-Domain Optical Coherence Tomography Imaging in 67 321 Adults: Associations with Macular Thickness in the UK Biobank Study. *Ophthalmology* 2016;123(4):829-40.
22. Ouyang Y, Heussen FM, Keane PA, Sadda SR, Walsh AC. The retinal disease screening study: prospective comparison of nonmydriatic fundus photography and optical coherence tomography for detection of retinal irregularities. *Invest Ophthalmol Vis Sci* 2013;54(2):1460-8.
23. Nicholson BP, Zhou M, Rostamizadeh M, Mehta P, Agron E, Wong W, et al. Epidemiology of epiretinal membrane in a large cohort of patients with uveitis. *Ophthalmology* 2014;121(12):2393-8.
24. Myers CE, Klein BE, Gangnon R, Sivakumaran TA, Iyengar SK, Klein R. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. *Ophthalmology* 2014;121(10):1949-55.
25. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves' ophthalmopathy and smoking. *Lancet* 1990;335(8700):1261-3.
26. Rong SS, Peng Y, Liang YB, Cao D, Jhanji V. Does cigarette smoking alter the risk of pterygium? A systematic review and meta-analysis. *Invest Ophthalmol Vis Sci* 2014;55(10):6235-43.

## Acknowledgments

This work was supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology (2016QN07), National Natural Science Foundation of China (81420108008) and Science and Technology Planning Project of Guangdong Province, China (2013B20400003).

## Author Contributions

Author MGH conceived and designed the study; Authors WX and XYC performed the literature search, study selection, data extraction and synthesis. Author WX prepared the draft manuscript; Authors WY, ZTZ and MGH were involved in the revision and final preparation of the manuscript.

## Competing financial interests

The Authors have no competing financial interests to report.

## Data Sharing Statement

No additional unpublished data are available

**Table 1.** Characteristics of included studies

Study	Country	Year	N(%male)	Age range	Race/Ethnicity	Eye examined	Pupil dilation	Fundus photography	Image grading	OCT used
BDES	USA	1987-88	4802	43-84	Caucasian	Both	Yes	30-degree; stereo; $\geq 3$ fields; film	Reading center at University of Wisconsin	No
Beixinjing*	China	2010-11	3326 (44.5)	50-98	Asian	Both	Yes	45-degree; non-stereo; 2 fields; digital	Ophthalmologists	No
BMES	Australia	1992-93	3490 (43.8)	$\geq 49$	Caucasian	Both	Yes	30-degree; stereo; 6 fields; film	Reading center at University of Sydney	No
Funagata	Japan	2000-02	1543 (43.4)	$\geq 35$	Asian	Right eye	No	45-degree; non-stereo; 1 field; film	Reading center at University of Sydney	No
HES	China	2006-07	6565 (46.7)	$\geq 30$	Asian	Both	Part of*	45-degree; non-stereo; 2 fields; digital	Ophthalmologists	Yes
Hisayama	Japan	1998	1765 (38.5)	$\geq 40$	Asian	Both	Yes	45-degree; non-stereo; 1 field; film	Ophthalmologists	No
Jiangning	China	2012-13	2005 (43.7)	$\geq 50$	Asian	Both	No	45-degree; non-stereo; $\geq 2$ fields; digital	Trained graders	Yes
LALES	USA	2000-03	5982 (42.0)	$\geq 40$	Hispanic	Both	Yes	30-degree; stereo, 3 fields; film	Reading center at University of Wisconsin	No
MESA	USA	2002-04	5960 (47.9)	45-84	White, Black; Asian; Hispanic	Both	No	45-degree; non-stereo; 2 fields; digital	Reading center at University of Wisconsin	No
SCES	Singapore	2009-11	3353	40-80	Asian	Both	Yes	45-degree; non-stereo; 2	Reading center at	No

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

								fields; digital	University of Sydney	
SiMES	Singapore	2004-06	3265 (48.1)	40-80	Asian	Both	Yes	45-degree; non-stereo; 2 fields; digital	Reading center at University of Sydney	No
SINDI	Singapore	2007-09	3328 (50.2)	40-80	Asian	Both	Yes	non-stereo; 2 fields; digital	Reading center at University of Sydney	No
VIP	Australia	1992-97	4313 (47.0)	≥40	Caucasian	Both	Yes	30-degree; stereo; 2 field; film	Reading center at University of Sydney	No

\* Data only available for primary ERMs.

For peer review only



**Table 2.** Age-standardised prevalence of epiretinal membrane by study

Study	Year	N at-risk	Crude prevalence (%)			Age-standardised prevalence (%; 95%CI)		
			CMR	PMF	Any ERM #	CMR	PMF	Any ERM #
<b>All ERM ##</b>								
BDES	1987-88	4802	-	-	-	4.8 (4.3-5.4)	1.7 (1.3-2.0)	6.4 (5.8-7.1)
BMES	1992-93	3490	4.8	2.7	7.0	3.8 (3.2-4.4)	1.7 (1.3-2.1)	5.5 (4.8-6.2)
Funagata	2000-02	1543	4.0	1.5	5.4	2.7 (1.9-3.4)	1.1 (0.6-1.5)	3.7 (2.8-4.6)
HES	2006-07	6565	2.2	0.7	3.4	2.3 (1.8-2.8)	0.6 (0.4-0.7)	3.5 (2.9-4.0)
Hisayama	1998	1765	3.2	0.9	4.0	2.2 (1.6-2.9)	0.5 (0.2-0.8)	2.8 (2.1-3.5)
Jiangning	2012-13	2005	5.0	3.4	8.4	4.5 (3.7-5.4)	3.1 (2.4-3.9)	7.6 (6.5-8.7)
LALES	2000-03	5982	16.3	2.2	18.5	16.6 (15.7-17.6)	2.5 (2.0-2.9)	19.0 (18.0-20.0)
MESA	2002-04	5960	25.1	3.8	28.9	21.5 (20.1-22.5)	3.0 (2.6-3.4)	24.5(23.4-25.6)
SIMES	2004-06	3265	5.8	5.9	11.8	4.7 (4.0-5.3)	4.6 (4.0-5.3)	9.3 (8.3-10.2)
SCES	2009-11	3353	-	-	-	7.0 (6.1-7.9)	7.5 (6.6-8.3)	13.0 (11.9-14.2)
SINDI	2007-09	3328	5.4	4.8	10.2	4.7 (4.0-5.3)	4.1 (3.4-4.7)	8.8 (7.9-9.7)
VIP	1992-97	4313	4.8	1.7	6.0	3.8 (3.3-4.4)	1.4 (1.1-1.8)	4.9 (4.4-5.5)
<b>Pooled estimates</b>	<b>NA</b>	<b>46371</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>6.5 (4.2-8.9)</b>	<b>2.6 (1.8-3.4)</b>	<b>9.1 (6.0-12.2)</b>
<i>I</i> <sup>2</sup>						99.3	98.2	99.5

<b>Primary ERM</b>								
BDES	1987-88	4125	-	-	-	4.5 (3.9-5.1)	1.3 (1.0-1.6)	5.8 (5.1-6.5)
Beixinjing	2010-11	3326	0.6	0.6	1.0	0.6 (0.3-0.9)	0.4 (0.2-0.6)	1.0 (0.6-1.3)
HES	2006-07	6196	2.0	0.5	3.0	2.1 (1.6-2.6)	0.4 (0.3-0.6)	3.1 (2.6-3.7)
Jiangning	2012-13	1854	4.6	3.1	7.7	4.3 (3.4-5.2)	3.0 (2.2-3.7)	7.3 (6.1-8.4)
LALES	2000-03	5631	15.6	1.9	17.5	16.1 (15.2-17.1)	2.2 (1.8-2.6)	18.4 (17.3-19.4)
MESA	2002-04	4761	22.7	3.3	26.1	20.2 (19.1-21.3)	2.7 (2.3-3.1)	23.0 (21.7-24.1)
SIMES	2004-06	2734	5.1	4.5	9.5	4.5 (3.7-5.2)	3.8 (3.2-4.5)	8.3 (7.3-9.3)
SINDI	2007-09	2324	3.8	2.7	6.5	4.3 (3.4-5.2)	2.8 (2.1-3.5)	7.0 (5.9-8.2)
<b>Pooled estimates</b>	<b>NA</b>	<b>30951</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>7.1 (3.3-10.8)</b>	<b>2.0 (1.3-2.8)</b>	<b>9.2 (4.7-13.8)</b>
$r^2$						99.6	97.9	99.7
<b>Secondary ERM</b>								
HES	2006-07	269	7.1	3.7	12.3	6.7 (1.9-11.5)	3.7 (0-7.8)	11.1 (5.0-17.3)
Jiangning	2012-13	151	10.6	6.6	17.2	7.0 (3.4-10.7)	3.9 (1.2-6.6)	10.9 (6.6-15.2)
LALES	2000-03	345	27.0	7.5	34.5	19.8 (14.4-25.2)	6.1 (2.9-9.3)	25.9 (20.0-31.9)
MESA	2002-04	1199	34.3	5.8	40.1	25.1 (22.2-28.1)	3.4 (2.5-4.4)	28.6 (25.6-31.6)
SIMES	2004-06	531	9.8	13.6	23.4	5.3 (2.5-8.1)	7.1 (5.2-9.0)	12.4 (9.1-15.7)
SINDI	2007-09	1004	9.1	9.8	18.8	5.1 (3.6-6.5)	6.0 (4.2-7.8)	11.0 (8.8-13.3)

<b>Pooled estimates</b>	<b>NA</b>	<b>3499</b>	-	-	-	<b>11.4 (4.4-18.5)</b>	<b>5.1 (3.5-6.6)</b>	<b>16.6 (9.7-23.6)</b>
$I^2$						97.0	69.4	95.4

#: Any ERM: both CMR and PMF.

##: All ERM: both primary and secondary ERM.

**Table 3.** Age-standardised prevalence of epiretinal membranes by subgroups of interest

	CMR			PMF			Any ERM			Reference
	Studies (n)	Prevalence (% , 95%CI)	I <sup>2</sup> (%)	Studies (n)	Prevalence (% , 95%CI)	I <sup>2</sup> (%)	Studies (n)	Prevalence (% , 95%CI)	I <sup>2</sup> (%)	
<b>Race/ethnicity</b>										
Caucasian	4	8.9 (4.6-13.2)	99.4	4	2.0 (1.4-2.7)	88.8	4	11.0 (5.9-16.1)	99.5	2, 6, 7, 10
Asian	8	6.5 (4.6-8.5)	98.2	8	3.6 (2.2-4.9)	98.7	8	10.5 (7.2-13.8)	99.1	3, 4, 5, 8, 9, 10, 16, 17
<b>WHO Regions</b>										
The Americas	3	14.3 (3.6-25.0)	99.8	3	2.4 (1.6-3.2)	91.6	3	14.4 (5.6-23.2)	99.7	2, 10, 11
Western Pacific	9	4.0 (3.1-4.9)	94.2	9	2.7 (1.7-3.7)	98.3	9	8.5 (4.7-8.4)	98.2	3, 4, 5, 6, 7, 8, 9, 16, 17
<b>Testing method</b>										
Photography only	10	7.2 (4.2-10.1)	99.5	10	2.8 (1.9-3.7)	97.8	10	9.1 (6.0-12.2)	99.3	2, 3, 4, 5, 6, 7, 10, 11, 16, 17
Photography + OCT	2	3.4 (1.2-5.5)	94.8	2	1.8 (0-3.7)	97.6	2	5.5 (1.5-9.5)	97.7	8, 9
<b>Photography</b>										
Film	6	5.6 (2.5-8.8)	99.3	6	1.5 (0.9-2.0)	92.2	6	7.0 (3.4-10.7)	99.4	2, 5, 6, 7, 11, 17
Digital	6	7.4 (3.2-11.7)	99.5	6	3.8 (1.9-5.7)	99.0	6	10.0 (5.7-14.3)	99.3	3, 4, 8, 9, 10, 16
<b>Image graded by</b>										

RC at UW–Madison <sup>#</sup>	3	14.3 (3.6-25.0)	99.8	3	2.4 (1.6-3.2)	91.6	3	14.4 (5.6-23.2)	99.7	2, 10, 11
RC at USYD <sup>##</sup>	6	4.4 (3.5-5.4)	92.3	6	3.4 (1.9-4.9)	98.1	6	7.5 (5.1-9.9)	98.1	3, 4, 5, 6, 7, 16
Ophthalmologists or trained raters	3	3.0 (1.7-4.2)	90.9	3	2.6 (1.8-3.4)	98.1	3	4.6 (2.3-6.8)	96.4	8, 9, 17

<sup>#</sup>: Reading center at University of Wisconsin-Madison;

<sup>##</sup>: Reading center at University of Sydney.

**Table 4.** Pooled odds ratios for risk of any epiretinal membrane

Risk factors	Studies	OR (95%CI)	I <sup>2</sup> (%)	Reference
Age (per year)	5	<b>1.19 (1.13, 1.26)</b>	95.1	3, 4, 5, 9, 10, 16
Sex (female)	6	<b>1.34 (1.17, 1.53)</b>	24.8	3, 4, 5, 9, 16, 17
Myopia (present)	4	1.21 (0.67, 2.19)	88.9	6, 8, 9, 16
Hyperopia (present)	3	1.23 (0.78, 1.94)	83.8	6, 8, 16
Hypertension (present)	6	1.04 (0.90, 1.20)	11.2	4, 5, 6, 9, 16, 17
Diabetes (present)	6	1.13 (0.92, 1.38)	17.1	4, 5, 6, 9, 16, 17
Smoking (present)	7	<b>0.67 (0.58, 0.78)</b>	0	3, 4, 5, 6, 8, 16, 17
Alcohol intake (present)	3	0.97 (0.75, 1.25)	0	6, 9, 17
Early AMD (present)	3	0.96 (0.63, 1.47)	60.7	2, 5, 6
BMI (per kg/m <sup>2</sup> )	5	0.99 (0.98, 1.01)	0	4, 5, 6, 9, 17
Hyperlipidemia (present)	4	1.05 (0.99, 1.11)	62.0	4, 5, 9, 17


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legends:**

**Figure 1.** Flow chart of studies identified, included, and excluded.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Flow chart of studies identified, included, and excluded

69x77mm (300 x 300 DPI)



# The Prevalence and Risk Factors of Epiretinal Membranes: Pooled Data from Population-Based Studies

Wei Xiao, Xiaoyun Chen, William Yan, Zhuoting Zhu, Mingguang He

## Literature search strategy

### Terms

1. prevalence, epidemiology, epidemic\*, risk
2. epiretinal membrane\*; erm\*; ierm\*; cellophane macular reflex; preretinal macular fibrosis

### Search strategy

#### PubMed (up to July 11, 2016)

#1	prevalence Fields: Title/Abstract	459388
#2	epidemiology Fields: Title/Abstract	143403
#3	epidemic* Fields: Title/Abstract	80597
#4	risk Fields: Title/Abstract	1507737
#5	#1 OR #2 OR #3 OR #4	1973101
#6	epiretinal membrane* Fields: Title/Abstract	2259
#7	ERM Fields: Title/Abstract	3126
#8	iERM Fields: Title/Abstract	23
#9	cellophane macular reflex Fields: All fields	18
#10	preretinal macular fibrosis Fields: All fields	69
#11	#6 OR #7 OR #8 OR #9 OR #10	4935
#12	#5 AND #11	569

#### Embase (up to July 11, 2016)

#1	prevalence	609473
----	------------	--------

	Fields: ti, ab	
#2	epidemiology Fields: ti, ab	144993
#3	epidemic* Fields: ti, ab	89089
#4	risk Fields: ti, ab	2059117
#5	#1 OR #2 OR #3 OR #4	2622649
#6	epiretinal membrane* Fields: ti, ab	2491
#7	ERM Fields: ti, ab	3555
#8	iERM Fields: ti, ab	22
#9	cellophane macular reflex Fields: All fields	18
#10	preretinal macular fibrosis Fields: All fields	75
#11	#6 OR #7 OR #8 OR #9 OR #10	5570
#12	#5 AND #11	619

### Web of Science (All Databases, 1980 to July 11, 2016)

#### All languages, all document types

#1	TS = prevalence	684438
#2	TS = epidemiology	1440407
#3	TS=epidemic*	100419
#4	TS=risk	2386116
#5	#1 OR #2 OR #3 OR #4	3597103
#6	TS=epiretinal membrane*	3045
#7	TS=ERM	369
#8	TS=iERM	21
#9	TS=cellophane macular reflex	17
#10	TS=preretinal macular fibrosis	67
#11	#6 OR #7 OR #8 OR #9 OR #10	6344
#12	#5 AND #11	956

**Table S1.** Appraisal criteria for study methodology

Quality Criteria	Maximum score
1. Representing the general population	1
2. Appropriately recruiting the population	1
3. Adequate response rate (>70%)	1
4. Objective documentation of the outcomes	1

For peer review only

**Table S2.** Quality score of included studies

Study	Representing the general population	Appropriately recruiting the population	Adequate response rate (>70%)	Objective documentation of the outcomes	Total score
BDES	1	1	1	1	4
Beixinjing	1	1	1	1	4
BMES	1	1	1	1	4
Funagata	1	1	0	1	3
HES	1	1	1	1	4
Hisayama	1	1	0	1	3
Jiangning	1	1	1	1	4
LALES	1	1	1	1	4
MESA	1	1	1	1	4
SCES	1	1	1	1	4
SiMES	1	1	1	1	4
SINDI	1	1	1	1	4
VIP	1	1	1	1	4

# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not available
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6, Suppl. info
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	8

# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10, table2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	table 2-4
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-11, table3
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1, 19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

# BMJ Open

## The prevalence and risk factors of epiretinal membranes: a systematic review and meta-analysis of population-based studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014644.R2
Article Type:	Research
Date Submitted by the Author:	31-Jul-2017
Complete List of Authors:	Xiao, Wei; Sun Yat-Sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Chen, Xiaoyun; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Yan, William; University of Melbourne, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital Zhu, Zhuoting; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center He, Mingguang; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center; University of Melbourne, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital
<b>Primary Subject Heading</b>:	Ophthalmology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Epiretinal membranes, Prevalence, Risk factors, Meta-analysis, Population-based

SCHOLARONE™  
Manuscripts

1  
2 **The prevalence and risk factors of epiretinal membranes: a systematic review**  
3  
4 **and meta-analysis of population-based studies**  
5

6  
7 Wei Xiao<sup>1</sup>, Xiaoyun Chen<sup>1</sup>, William Yan<sup>2</sup>, Zhuoting Zhu<sup>1</sup>, Mingguang He<sup>1,2,\*</sup>  
8  
9

10 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun  
11

12 Yat-sen University, Guangzhou, China  
13

14 2. Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye  
15

16 and Ear Hospital, Australia  
17  
18

19  
20 **\* Correspondence:**  
21

22 Mingguang He, M.D, Ph.D, FRANZCO  
23

24 Associate Director & Professor, Zhongshan Ophthalmic Center, Guangzhou 510060,  
25

26 People's Republic of China  
27

28  
29 Tel: (86) 20 87331109; Fax: (86) 20 87331903  
30  
31

32 Email: mingguang.he@unimelb.edu.au  
33  
34

35 **Running head:** The prevalence and risk factors of ERM  
36

37 **Financial support:** The Fundamental Research Funds of the State Key Laboratory  
38

39 of Ophthalmology (2016QN07), National Natural Science Foundation of China  
40

41 (81420108008) and Science and Technology Planning Project of Guangdong  
42

43 Province, China (2013B20400003). Dr. Mingguang He receives support from the  
44

45 University of Melbourne Research at Melbourne Accelerator Program Professorship.  
46

47 The Centre for Eye Research Australia receives operational infrastructural support  
48

49 from the Victorian government. Sponsor or funding organization had no role in the  
50

51 design or conduct of this research.  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Abstract

**Objective:** This study was to aggregate the prevalence and risks of ERMs, and determine the possible causes of the varied estimates.

**Design:** Systematic review and meta-analysis.

**Data sources:** The search strategy was designed prospectively. We searched PubMed, Embase and Web of Science databases from inception to July 2016. Reference lists of the included literatures were reviewed as well.

**Study selection:** Surveys published in English language from any population were included if they had a population-based design, and reported the prevalence of ERM from retinal photography with or without optical coherence tomography (OCT). Eligibility and quality evaluation was conducted independently by two investigators.

**Data extraction:** The literature search generated 2,144 records, and thirteen population-based studies comprising 49,697 subjects were finally included. The prevalence of ERM, and the odds ratios of potential risk factors (age, sex, myopia, hypertension, etc.) were extracted.

**Results:** The pooled age-standardised prevalence estimates of earlier ERM (cellophane macular reflex, CMR), advanced ERM (preretinal macular fibrosis, PMF) and any ERM were 6.5% (95%CI: 4.2 to 8.9), 2.6% (95%CI: 1.8 to 3.4), and 9.1% (95%CI: 6.0 to 12.2), respectively. In the subgroup analysis, race and photography modality contributed to the variation in the prevalence estimates of PMF, while the WHO regions and image reading methods were associated with the varied prevalence of CMR and any ERM. Meta-analysis showed that only greater age and female significantly conferred a higher risk of ERMs.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Conclusions:** Our findings suggest that ERMs are relatively common among aged population. Race, image taking and reading methodology may play important roles in influencing the large variability of ERM prevalence estimates.

**Keywords:** Epiretinal membranes, Prevalence, Risk factors, Meta-analysis, Population-based

For peer review only

## Strengths and limitations of this study

- This study is the first systematic review and meta-analysis that pools the age-standardised prevalence of epiretinal membrane (ERM) from population-based studies.
- The investigators strictly adhered to the guidelines for systematic review and meta-analysis. All included surveys were of desirable quality and large-scale.
- We aggregated not only the prevalence of ERM but also its subtype estimates (CMR and PMF).
- Lack of studies from the African and European continents makes it difficult to project ERM prevalence estimates worldwide.
- We are unable to aggregate the data on the relationship between ERM prevalence and visual acuity impairment due to lack of studies on their association.
- We only included literatures in English for the present analysis.

## INTRODUCTION

Epiretinal membranes (ERMs) are common retinal conditions that can impair visual acuity in old persons. ERMs may occur without any antecedent ocular conditions or surgical procedures, termed idiopathic or primary ERM. Those associated with other eye diseases (e.g. retinal vascular occlusion, diabetic retinopathy), trauma or surgery are referred to as secondary ERM. Under ophthalmoscopy, earlier stage ERMs present as increases of the light reflex from the retina inner surface, which is called cellophane macular reflex (CMR). As the membrane progresses, it can contract and create superficial retinal folds. Massive folds make the retina appear with gray linear reflexes, which are termed preretinal macular fibrosis (PMF). For most cases at the advanced stage, fibrotic membranes generate tangential traction on the macula, causing macular oedema, metamorphopsias and central vision impairment<sup>1</sup>.

After the landmark study Beaver Dam Eye Study (BDES) reported the prevalence of ERM in 1994<sup>2</sup>, several large-scale population-based studies investigated the epidemics of ERMs in Singapore<sup>3 4</sup>, Japan<sup>5</sup>, Australia<sup>6 7</sup> and China<sup>8 9</sup>. Most of these surveys introduced retinal photography, and the same classification scheme for ERMs as that in BDES. However, considerable variation in ERM epidemiology across races and regions has been noted. For example, in the population-based Multi-Ethnic Study of Atherosclerosis (MESA)<sup>10</sup>, ERM was as prevalent as 39.0% in Chinese, 27.5% in Caucasian, 26.2% in Africans, and 29.3% in Hispanics. These estimates were much higher than those in the Handan Eye Study in North China (3.4%)<sup>8</sup>, the Blue Mountains Eye Study (BMES) in Australia (7%)<sup>7</sup>, and the Los Angeles Latino Eye

1  
2 Study in the US (19.9%)<sup>11</sup>. Reasons for such variability may be complex, but it has  
3  
4 been considered to be associated with the differences in study design, population  
5  
6 characteristics, as well as the definition of cases. Moreover, some studies did not  
7  
8 compute the age-standardised estimates of prevalence, making direct comparison  
9  
10 between studies difficult.  
11  
12

13  
14  
15  
16  
17 Estimating the prevalence and risk of ERM is perhaps the first step to better clinical  
18  
19 management, and understanding the burden of this disease. Therefore, we  
20  
21 conducted the present analysis to synthesise data from population-based studies to  
22  
23 estimate the prevalence of ERMs, to identify underlying factors causing prevalence  
24  
25 variability as well as major risk factors for ERMs.  
26  
27  
28  
29  
30  
31

## 32 **METHODS**

33  
34  
35 In this study, we followed the preferred reporting items for systematic reviews and  
36  
37 meta-analyses (the PRISMA statement<sup>12</sup>, see Supplementary Information).  
38  
39  
40  
41

### 42 **Search strategy and selection criteria**

43  
44  
45 The search strategy was designed prospectively. We searched all reports on  
46  
47 population-based studies for the prevalence of ERMs using PubMed, Embase and  
48  
49 Web of Science from inception to July 2016. All English language articles were  
50  
51 retrieved using pre-specified search terms. The search terms and strategies were  
52  
53 showed in detail in Supplementary information. The reference lists of all included  
54  
55 articles were reviewed, and the full texts of potentially related papers were examined.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 We designed a set of inclusion and exclusion criteria for literature screening. Studies  
6  
7 included were those population-based surveys in which ERMs were diagnosed on the  
8  
9 basis of retinal colour photography with or without a combination of optical coherence  
10  
11 tomography (OCT). Studies without population-based (e.g., hospital- or specific  
12  
13 population-based) design were excluded. Eligibility evaluation was conducted  
14  
15 independently by two investigators (W.X and X.Y.C) using pre-designed forms. Any  
16  
17 disagreements were resolved by consensus.  
18  
19  
20  
21  
22  
23  
24

### 25 **Quality assessment and data extraction**

26  
27 There were no consensus guidelines on evaluating cross-sectional surveys, so we  
28  
29 adopted the quality assessment criteria used by de Weerd et al<sup>13</sup> and Rogers S et al<sup>14</sup>.  
30  
31 The criteria covered the following four aspects (Supplementary Information): 1)  
32  
33 Representing the general population. To achieve this, studies should be undertaken  
34  
35 using population registries, inhabitants of a specific area, or people registered with a  
36  
37 general practice. 2) Appropriately recruiting the population. Recruitment was  
38  
39 considered appropriate if it was performed randomly or consecutively rather than for  
40  
41 convenience or from volunteers. 3) Adequate response rate (>70%). 4) Objective  
42  
43 documentation of the outcomes. That means documentation of ERMs by retinal  
44  
45 photography according to standardised protocols and graded according to standard  
46  
47 definitions. Fulfillment of 3 or 4 points was considered adequate quality. Quality of all  
48  
49 included studies was assessed independently by two investigators (W.X and X.Y.C)  
50  
51 using quality assessment forms based on the aforementioned criteria.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 For included studies, data were extracted independently by two reviewers (W.X and  
6  
7 X.Y.C) on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft,  
8  
9 Redmond, Washington, USA). Discrepancies were resolved by consensus. We  
10  
11 extracted the following data from each study: country, year, sample size, age range,  
12  
13 race/ethnicity, examination methods, image grading approach, crude prevalence with  
14  
15 95% confidence interval (95%CI), and odds ratios (ORs) with 95%CI for risk factors  
16  
17 (including age, gender, refractive error, hypertension, diabetes, smoking status,  
18  
19 alcohol intake, early AMD, body mass index and hyperlipidaemia). Our key outcomes  
20  
21 of interest were the prevalence and risk factors of ERM.  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Data synthesis and statistical analysis**

31  
32 Age-standardised prevalence of ERMs in each study was calculated by projecting its  
33  
34 crude prevalence rates to the WHO world standard age-structure<sup>15</sup>. This method has  
35  
36 been adopted to estimate the regional and global prevalence and burden of several  
37  
38 major eye diseases, such as age-related macular degeneration<sup>16</sup>, diabetic  
39  
40 retinopathy<sup>17</sup> and retinal vein occlusion<sup>14</sup>. The  $I^2$  statistic was used to estimate  
41  
42 heterogeneity between studies with a value greater than 50% as significantly  
43  
44 heterogeneous. Due to the marked difference between studies, pooled prevalence  
45  
46 was synthesised using random-effect models<sup>18</sup>. Sources of heterogeneity were  
47  
48 explored by conducting subgroup analysis accordingly to race/ethnicity, WHO regions,  
49  
50 testing method (photography with or without OCT), photography technique (digital or  
51  
52 film), and image grading approach (centralised grading centre vs. independently  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 trained graders). To aggregate odds ratios (ORs) for potential risk factors,  
3  
4 random-effect models were used if included studies were significantly heterogeneous  
5  
6 ( $I^2 \geq 50\%$ ); otherwise, fixed-effect models were used. All statistical analysis was  
7  
8 performed with STATA software (version 13.0, StataCorp LP, TX, USA).  
9  
10  
11  
12  
13

## 14 RESULTS

15  
16  
17 Figure 1 exhibits the procedure of literature searching and screening. The systematic  
18  
19 searches yielded 2,144 records. After removing 906 duplications, 1,238 studies were  
20  
21 screened through titles and abstracts. Among them, we ruled out 1,186 irrelevant  
22  
23 articles and reviewed the left 52 studies in full text. Finally, we identified 13 studies<sup>2,3</sup>  
24  
25<sup>5-11 19-21</sup> that were eligible for inclusion (Table 1). Across the 13 studies, sample sizes  
26  
27 ranged from 1,543<sup>5</sup> to 6,565<sup>8</sup>, including 49,697 individuals at risk of ERMs. Two  
28  
29 studies (Funagata and Hisayama) scored 3 points in the quality assessment owing to  
30  
31 their relatively low response rate (<70%), while the others all scored 4 points (see  
32  
33 Supplementary Information). The Beixinjing Study<sup>21</sup> reported specifically on the  
34  
35 prevalence of primary (idiopathic) ERM, whereas the other 12 study documented the  
36  
37 prevalence of any ERM (i.e. both primary and secondary ERM). Geographically, the  
38  
39 WHO regions of Western Pacific Region and the Americas were heavily represented,  
40  
41 with all 13 studies done in these two regions. In other words, no studies had been  
42  
43 done in the European, Africa, South-East Asian or Eastern Mediterranean regions. Of  
44  
45 these 13 studies, 12 studies (all except Funagata<sup>5</sup>) assessed ERMs using both eyes  
46  
47 of each participant; 9 studies performed photography after pharmacologic mydriasis.  
48  
49 The methods of photography varied between studies, with 4 studies using  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2 stereo-photographing (vs. 9 using non-stereo photographing), 4 studies using  
3  
4 30-degree camera (vs. 9 using 45-degree camera) and 6 using film photography (vs.  
5  
6 7 using digital photography). Retinal images were graded at the reading centres at  
7  
8 the University of Wisconsin-Madison (3 studies), at the University of Sydney (7  
9  
10 studies), or by independent ophthalmologists/trained graders (4 studies).

11  
12  
13  
14  
15 Characteristics of the included studies were summarised in Table 1.

16  
17  
18  
19  
20 Analyses of the 12 studies concerning any ERM (except the Beixinjing Study  
21  
22 exclusively on primary ERM) showed that the overall age-standardised prevalence of  
23  
24 CMR was 6.5% (95% CI 4.2-8.9), PMF was 2.6% (95% CI 1.8-3.4), and any ERM  
25  
26 was 9.1% (95% CI 6.0-12.2) (Table 2). Specific to primary ERM, the pooled  
27  
28 prevalence of CMR, PMF and all primary ERM were 7.1% (95%CI 3.3-10.8), 2.0%  
29  
30 (95%CI 1.3-2.8) and 9.2% (95%CI 4.7-13.8), respectively. Six studies reported the  
31  
32 prevalence of secondary ERM, and all explicitly defined the population at-risk as  
33  
34 those with other ocular conditions (e.g. retinal vascular disease, retinal detachment)  
35  
36 or cataract surgery. The aggregated data showed the prevalence of secondary CMR,  
37  
38 PMF and any ERM were 11.4% (95%CI 4.4-18.5), 5.1% (95%CI 3.5-6.6) and 16.6%  
39  
40 (95%CI 9.7-23.6), respectively.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 The age-standardised prevalence of ERMs by subgroups of interest was shown in  
51  
52 Table 3. The aggregated prevalence of any ERM varied according to the WHO  
53  
54 regions, different image acquisition and grading method. Three studies from the  
55  
56 Americas, in which retinal images were also graded by the reading centre at the  
57  
58  
59  
60

1  
2 University of Wisconsin-Madison<sup>2 10 11</sup>, documented a much higher prevalence  
3  
4 (14.4%) than those from Western Pacific region (8.5%). Of note, this trend was  
5  
6 potentially attributed to the extremely high prevalence of CMR in the Americas (14.3%  
7  
8 vs. 4.0% in Western Pacific region). For PMF, the advanced stage of ERM, studies  
9  
10 using film photography synthesised a much lower prevalence than that using digital  
11  
12 photography (1.5% vs. 3.1%). PMF was slightly more prevalent in Asians than in  
13  
14 Caucasians (3.6% vs. 2.5%). There were only two studies from China introduced  
15  
16 OCT to confirm ERM cases<sup>8 9</sup>. Intriguingly, studies with a combination of OCT  
17  
18 demonstrated lower prevalence in both CMR (3.4% vs. 7.2% without OCT) and PMF  
19  
20 (1.8% vs. 2.8% without OCT).  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 As expected, individuals with greater age were more likely to have any ERM  
31  
32 (OR=1.19 per year increase, 95%CI 1.13-1.26). Compared to males, females carried  
33  
34 higher risk of ERM (OR=1.34, 95%CI 1.17-1.53). Smokers had an unexpected lower  
35  
36 risk of ERM compared to non-smokers (OR=0.67, 95%CI 0.58-0.78). Other factors  
37  
38 analysed, including myopia, hyperopia, hypertension, diabetes, alcohol intake, early  
39  
40 age-related macular degeneration, body mass index and hyperlipidaemia, were not  
41  
42 associated with the risk of any ERM (Table 4).  
43  
44  
45  
46  
47  
48  
49

## 50 DISCUSSION

51  
52 This study provides estimates for the prevalence of ERMs and its two stages using  
53  
54 data from most appropriate population-based studies in the literature. Using data from  
55  
56 13 studies with 49,697 participants, we estimated the age-standardised prevalence of  
57  
58  
59  
60

1  
2 any ERM (both primary and secondary) to be as high as 9.1%, with CMR and PMF as  
3  
4 6.5% and 2.6%, respectively. Race, retinal image taking and grading method were  
5  
6 responsible for the variation of the prevalence estimates across studies. Among the  
7  
8 factors analysed, greater age and female sex were significantly associated with  
9  
10 higher risk of developing ERMs.  
11  
12

13  
14  
15  
16  
17 The prevalence of ERM has been documented over the last 30 years in several  
18  
19 population-based surveys. However, these estimates have varied considerably  
20  
21 across studies. For example, the prevalence of any ERM has been estimated to be  
22  
23 35.7% in Latinos aged 70 to 79 years<sup>11</sup>, which was five-fold more prevalent than that  
24  
25 in the same age Japanese (6.8%)<sup>20</sup>. To form an age-standardised estimate of ERM  
26  
27 prevalence, and further to explore possible sources of heterogeneity, we conducted  
28  
29 this study to synthesise the best available data. In this review, we identified 13 eligible  
30  
31 studies with favorable quality, but they were predominantly carried out in Pacific Rim  
32  
33 countries (the USA, Australia, Japan, Singapore and China). Further study is  
34  
35 warranted in European and African regions so that we can generate the global  
36  
37 prevalence, and magnitude of this disease.  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Previously, ERM susceptibility has been reported to vary between ethnic groups.  
48  
49 MESA<sup>10</sup> was the only study that directly compared the racial and ethnic differences of  
50  
51 ERM prevalence within the same cohort. It reported a significantly higher prevalence  
52  
53 rate for Chinese ethnicity (39.0%), followed by Hispanic (29.3%), Caucasian (27.5%),  
54  
55 and African (26.2%) ethnicity. However, the sample sizes of each ethnic group were  
56  
57  
58  
59  
60

1  
2 relatively small, particularly in the Chinese subgroup (n=724). However, our  
3  
4 aggregated data of large sample size showed that ethnicity was less likely to be  
5  
6 associated with ERM prevalence disparities. The prevalence difference between  
7  
8 Asians and Caucasians for CMR and any ERM was negligible, indicating that  
9  
10 race/ethnicity may have a limited role in ERM prevalence.  
11  
12  
13  
14  
15  
16  
17

18 Our review shows that the variations in ERM prevalence between studies may be  
19  
20 partly attributed to their methodological characteristics. In terms of image grading  
21  
22 protocol, although all included studies consistently adopted the same classification  
23  
24 scheme as that in the Beaver Dam Eye Study<sup>2</sup>, retinal images were graded in  
25  
26 different fashions: 3 studies were read by the grading centre of the University of  
27  
28 Wisconsin-Madison in the US, 6 at the grading centre at the University of Sydney,  
29  
30 and the others graded by ophthalmologists or independently trained graders. In our  
31  
32 subgroup analysis, three studies graded at the reading centre at University of  
33  
34 Wisconsin-Madison pooled an extremely high prevalence of CMR and any ERM (14.3%  
35  
36 and 14.4%, respectively). Due to all three studies from the Americas, differences in  
37  
38 image reading patterns directly led to the regional differences in CMR and any ERM  
39  
40 prevalence estimates. Taken account of the minimal difference in the synthesised  
41  
42 PMF prevalence across reading centres, we could speculate that the substantial  
43  
44 differences in estimated overall ERM prevalence originated from the systematic  
45  
46 differences in grading CMR from retinal images. Accordingly, there is insufficient  
47  
48 evidence to conclude whether the regional difference in ERM prevalence is  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 attributable to the difference in geographical location *per se* or to the grading  
3 methodology. To address this issue, universal criteria for grading CMR and  
4  
5  
6  
7 differentiation from normal fundus manifestations may need to be further  
8  
9  
10 standardised.

11  
12  
13 Interestingly, unlike CMR and any ERM, the pooled prevalence of PMF across  
14  
15 regions were quite similar, but this prevalence was more likely to be affected by race  
16  
17 and photography modality (film vs. digital). Asians had a slightly higher prevalence of  
18  
19 PMF (3.6% vs. 2.0% in Caucasians), and digital photography seemed to detect more  
20  
21 PMF cases than film photography (3.8% vs. 1.5%).  
22  
23  
24  
25  
26  
27

28  
29 Optical coherence tomography (OCT) has been applied as the “gold standard” in  
30  
31 diagnosing vitreoretinal interface diseases in recent epidemiological studies<sup>22-24</sup>. In  
32  
33 clinical practice, OCT was superior to retinal photography in screening epiretinal  
34  
35 irregularities<sup>25</sup> and detecting subtle ERMs among special cases, such as those with  
36  
37 uveitis<sup>26</sup>. It follows that theoretically; studies using both photography and OCT should  
38  
39 detect more persons with ERMs. However, we unexpectedly found that two studies  
40  
41 using OCT produced much lower prevalence rates of CMR, PMF and any ERM than  
42  
43 the others without using it. A hypothesis explaining this apparent contradiction might  
44  
45 be that OCT may exclude ERM suspects based on colour retinal images. For  
46  
47 example, OCT is capable of differentiating ERM from posterior vitreous detachment  
48  
49 (PVD), another condition which frequently affect the elderly and resemble CMR on  
50  
51 colour retinal images. Further research is needed to assess the performance and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 cost-effectiveness of OCT in diagnosing ERMs prior to its adoption as the  
3  
4 gold-standard test for epidemiological studies across the board.  
5  
6  
7

8  
9  
10 For pooled risk estimates, our data showed that only age and sex were significantly  
11 associated the risk of any ERMs. Older and female individuals had higher risk of ERM  
12 from the meta-analysis (OR=1.19 and 1.34, respectively). With increasing age of the  
13 global population, ERM needs to be considered in a similar vein as age-related  
14 macular degeneration, a condition that significantly affects the aging population. In  
15 terms of systemic and ophthalmic risk factors, no significant association was found  
16 between ERM and diabetes, hypertension, hyperlipidaemia, BMI, myopia and early  
17 AMD.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 Cigarette smoking, on one hand, is a well-documented risk factor for several eye  
33 diseases, including age-related macular degeneration<sup>27</sup> and thyroid-associated  
34 ophthalmopathy<sup>28</sup>. On the other, smoking can also serve as a protective factor  
35 against the development of pterygium<sup>29</sup>. Our analysis convinced a negative  
36 association of ERM and smoking as well. This may be explained by a survival bias of  
37 smokers that cannot be excluded from cross-sectional analysis. So these findings  
38 should not discredit the importance of smoking cessation across populations.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 Strengths of the present study include the large sample size, specific and inclusive  
53 nature of criteria for population-based studies, and the inclusion of ERM subtype  
54 estimates (CMR and PMF). The pooled data provide a precise estimate of the ERM  
55  
56  
57  
58  
59  
60

1  
2 age-standard prevalence in the American and Asian-pacific population. However, our  
3  
4 study contains several limitations as well. First, significant heterogeneity across  
5  
6 studies existed in most of our analysis. Although we found that retinal image  
7  
8 acquisition and grading methods might partly account for the heterogeneity, pooled  
9  
10 prevalence estimates in each subgroup were still heterogeneous (all  $I^2 > 50\%$ , Table  
11  
12 2 and 3). Second, the lack of studies from the African and European continents  
13  
14 makes it difficult to estimate the global prevalence and magnitude of ERMs. Third,  
15  
16 samples from different study designs had considerably different inclusion criteria,  
17  
18 participant selection processes, and study protocols. For example, sample  
19  
20 populations were found to have considerably differences in proportions of subjects  
21  
22 with cardiovascular disease or diabetes complications<sup>9-11</sup>. Fourth, although ERMs,  
23  
24 especially PMF, can cause moderate to severe visual impairment and  
25  
26 metamorphopsias<sup>4</sup>, most studies did not quantitatively analysed the association  
27  
28 between ERMs and visual acuity. In this study, we are consequently unable to  
29  
30 aggregate the data on their relationship.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 CONCLUSIONS

43  
44 In conclusion, our current study provides the first estimate of ERM and its different  
45  
46 subtypes based on a pooled analysis of more than 40,000 participants from 13  
47  
48 studies in the US and the Western Pacific region. Our study shows that 9.1% of  
49  
50 general population had some form of ERMs, 6.5% had CMR, and 2.6% had the  
51  
52 advanced form of PMF. These data suggest that ERMs have the potential to be a  
53  
54 major cause of visual impairment. In some specific regions, such as Europe and  
55  
56  
57  
58  
59  
60

1  
2 Africa, robust evidence for the prevalence and risk of ERM is absent. To address  
3  
4 these gaps in the evidence, high quality epidemiological research is needed that  
5  
6 focuses specifically on these countries using standardised measures of diseases.  
7  
8

9  
10 Finally, we confirmed the significance and impact of two major factors, being age and  
11  
12 sex, on the risk of ERMs.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## REFERENCES

1. Bu SC, Kuijjer R, Li XR, Hooymans JM, Los LI. Idiopathic epiretinal membrane. *Retina* 2014;34(12):2317-35.
2. Klein R, Klein BE, Wang Q, Moss SE. The epidemiology of epiretinal membranes. *Trans Am Ophthalmol Soc* 1994;92:403-25.
3. Koh V, Cheung CY, Wong WL, Cheung CM, Wang JJ, Mitchell P, et al. Prevalence and risk factors of epiretinal membrane in Asian Indians. *Invest Ophthalmol Vis Sci* 2012;53(2):1018-22.
4. Cheung N, Tan SP, Lee SY, Cheung GC, Tan G, Kumar N, et al. Prevalence and risk factors for epiretinal membrane: the Singapore Epidemiology of Eye Disease study. *Br J Ophthalmol* 2016.
5. Kawasaki R, Wang JJ, Sato H, Mitchell P, Kato T, Kawata S, et al. Prevalence and associations of epiretinal membranes in an adult Japanese population: the Funagata study. *Eye (Lond)* 2009;23(5):1045-51.
6. McCarty DJ, Mukesh BN, Chikani V, Wang JJ, Mitchell P, Taylor HR, et al. Prevalence and associations of epiretinal membranes in the visual impairment project. *Am J Ophthalmol* 2005;140(2):288-94.
7. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. *Ophthalmology* 1997;104(6):1033-40.
8. Duan XR, Liang YB, Friedman DS, Sun LP, Wei WB, Wang JJ, et al. Prevalence and associations of epiretinal membranes in a rural Chinese adult population: the Handan Eye Study. *Invest Ophthalmol Vis Sci* 2009;50(5):2018-23.
9. Ye H, Zhang Q, Liu X, Cai X, Yu W, Yu S, et al. Prevalence and associations of epiretinal membrane in an elderly urban Chinese population in China: the Jiangning Eye Study. *Br J Ophthalmol* 2015;99(12):1594-7.
10. Ng CH, Cheung N, Wang JJ, Islam AF, Kawasaki R, Meuer SM, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population. *Ophthalmology* 2011;118(4):694-9.
11. Fraser-Bell S, Ying-Lai M, Klein R, Varma R. Prevalence and associations of epiretinal membranes in latinos: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2004;45(6):1732-6.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.
13. de Weerd M, Greving JP, de Jong AW, Buskens E, Bots ML. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis. *Stroke* 2009;40(4):1105-13.
14. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. *Ophthalmology* 2010;117(2):313-9 e1.
15. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age standardization of rates: a new who standard. Geneva: World Health Organization. Available at: <http://www.who.int/healthinfo/paper31.pdf>. 2001:(Accessed: 20th June 2015).

16. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. *Ophthalmology* 2010;117(5):921-7.
17. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care* 2012;35(3):556-64.
18. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010;1(2):97-111.
19. Kawasaki R, Wang JJ, Mitchell P, Aung T, Saw SM, Wong TY. Racial difference in the prevalence of epiretinal membrane between Caucasians and Asians. *Br J Ophthalmol* 2008;92(10):1320-4.
20. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Iida M, Ishibashi T, et al. Prevalence and risk factors for epiretinal membranes in a Japanese population: the Hisayama study. *Graefes Arch Clin Exp Ophthalmol* 2003;241(8):642-6.
21. Zhu XF, Peng JJ, Zou HD, Fu J, Wang WW, Xu X, et al. Prevalence and risk factors of idiopathic epiretinal membranes in Beixinjing blocks, Shanghai, China. *PLoS One* 2012;7(12):e51445.
22. Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. *Sci Rep* 2016;6:21090.
23. Meuer SM, Myers CE, Klein BE, Swift MK, Huang Y, Gangaputra S, et al. The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography: the beaver dam eye study. *Ophthalmology* 2015;122(4):787-95.
24. Patel PJ, Foster PJ, Grossi CM, Keane PA, Ko F, Lotery A, et al. Spectral-Domain Optical Coherence Tomography Imaging in 67 321 Adults: Associations with Macular Thickness in the UK Biobank Study. *Ophthalmology* 2016;123(4):829-40.
25. Ouyang Y, Heussen FM, Keane PA, Sadda SR, Walsh AC. The retinal disease screening study: prospective comparison of nonmydriatic fundus photography and optical coherence tomography for detection of retinal irregularities. *Invest Ophthalmol Vis Sci* 2013;54(2):1460-8.
26. Nicholson BP, Zhou M, Rostamizadeh M, Mehta P, Agron E, Wong W, et al. Epidemiology of epiretinal membrane in a large cohort of patients with uveitis. *Ophthalmology* 2014;121(12):2393-8.
27. Myers CE, Klein BE, Gangnon R, Sivakumaran TA, Iyengar SK, Klein R. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. *Ophthalmology* 2014;121(10):1949-55.
28. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves' ophthalmopathy and smoking. *Lancet* 1990;335(8700):1261-3.
29. Rong SS, Peng Y, Liang YB, Cao D, Jhanji V. Does cigarette smoking alter the risk of pterygium? A systematic review and meta-analysis. *Invest Ophthalmol Vis Sci* 2014;55(10):6235-43.

## Acknowledgments

This work was supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology (2016QN07), National Natural Science Foundation of China (81420108008) and Science and Technology Planning Project of Guangdong Province, China (2013B20400003).

## Author Contributions

Author MGH conceived and designed the study; Authors WX and XYC performed the literature search, study selection, data extraction and synthesis. Author WX prepared the draft manuscript; Authors WY, ZTZ and MGH were involved in the revision and final preparation of the manuscript.

## Competing financial interests

The Authors have no competing financial interests to report.

## Data Sharing Statement

No additional unpublished data are available

**Table 1.** Characteristics of included studies

Study	Country	Year	N(%male)	Age range	Race/Ethnicity	Eye examined	Pupil dilation	Fundus photography	Image grading	OCT used
BDES	USA	1987-88	4802	43-84	Caucasian	Both	Yes	30-degree; stereo; $\geq 3$ fields; film	Reading centre at University of Wisconsin	No
Beixinjing*	China	2010-11	3326 (44.5)	50-98	Asian	Both	Yes	45-degree; non-stereo; 2 fields; digital	Ophthalmologists	No
BMES	Australia	1992-93	3490 (43.8)	$\geq 49$	Caucasian	Both	Yes	30-degree; stereo; 6 fields; film	Reading centre at University of Sydney	No
Funagata	Japan	2000-02	1543 (43.4)	$\geq 35$	Asian	Right eye	No	45-degree; non-stereo; 1 field; film	Reading centre at University of Sydney	No
HES	China	2006-07	6565 (46.7)	$\geq 30$	Asian	Both	Part of*	45-degree; non-stereo; 2 fields; digital	Ophthalmologists	Yes
Hisayama	Japan	1998	1765 (38.5)	$\geq 40$	Asian	Both	Yes	45-degree; non-stereo; 1 field; film	Ophthalmologists	No
Jiangning	China	2012-13	2005 (43.7)	$\geq 50$	Asian	Both	No	45-degree; non-stereo; $\geq 2$ fields; digital	Trained graders	Yes
LALES	USA	2000-03	5982 (42.0)	$\geq 40$	Hispanic	Both	Yes	30-degree; stereo, 3 fields; film	Reading centre at University of Wisconsin	No
MESA	USA	2002-04	5960 (47.9)	45-84	White, Black; Asian; Hispanic	Both	No	45-degree; non-stereo; 2 fields; digital	Reading centre at University of Wisconsin	No
SCES	Singapore	2009-11	3353	40-80	Asian	Both	Yes	45-degree; non-stereo; 2	Reading centre at	No

								fields; digital	University of Sydney	
SiMES	Singapore	2004-06	3265 (48.1)	40-80	Asian	Both	Yes	45-degree; non-stereo; 2 fields; digital	Reading centre at University of Sydney	No
SINDI	Singapore	2007-09	3328 (50.2)	40-80	Asian	Both	Yes	non-stereo; 2 fields; digital	Reading centre at University of Sydney	No
VIP	Australia	1992-97	4313 (47.0)	≥40	Caucasian	Both	Yes	30-degree; stereo; 2 field; film	Reading centre at University of Sydney	No

BDES, the Beaver Dam Eye Study; BMES, the Blue Mountains Eye Study; Funagata, the Funagata study; HES, the Handan Eye Study; Hisayama, the Hisayama study; Jiangning, the Jiangning Eye Study; LALES, the Los Angeles Latino Eye Study; MESA, the Multi-Ethnic Study of Atherosclerosis; SiMES, the Singapore Malay Eye Study; SCES, the Singapore Chinese Eye Study; SINDI, the Singapore Indian Eye study; VIP, the Visual Impairment Project; OCT, optical coherence tomography.

\* Data only available for primary ERMs.

**Table 2.** Age-standardised prevalence of epiretinal membrane by study

Study	Year	N at-risk	Crude prevalence (%)			Age-standardised prevalence (%; 95%CI)		
			CMR	PMF	Any ERM #	CMR	PMF	Any ERM #
<b>All ERM ##</b>								
BDES	1987-88	4802	-	-	-	4.8 (4.3-5.4)	1.7 (1.3-2.0)	6.4 (5.8-7.1)
BMES	1992-93	3490	4.8	2.7	7.0	3.8 (3.2-4.4)	1.7 (1.3-2.1)	5.5 (4.8-6.2)
Funagata	2000-02	1543	4.0	1.5	5.4	2.7 (1.9-3.4)	1.1 (0.6-1.5)	3.7 (2.8-4.6)
HES	2006-07	6565	2.2	0.7	3.4	2.3 (1.8-2.8)	0.6 (0.4-0.7)	3.5 (2.9-4.0)
Hisayama	1998	1765	3.2	0.9	4.0	2.2 (1.6-2.9)	0.5 (0.2-0.8)	2.8 (2.1-3.5)
Jiangning	2012-13	2005	5.0	3.4	8.4	4.5 (3.7-5.4)	3.1 (2.4-3.9)	7.6 (6.5-8.7)
LALES	2000-03	5982	16.3	2.2	18.5	16.6 (15.7-17.6)	2.5 (2.0-2.9)	19.0 (18.0-20.0)
MESA	2002-04	5960	25.1	3.8	28.9	21.5 (20.1-22.5)	3.0 (2.6-3.4)	24.5(23.4-25.6)
SIMES	2004-06	3265	5.8	5.9	11.8	4.7 (4.0-5.3)	4.6 (4.0-5.3)	9.3 (8.3-10.2)
SCES	2009-11	3353	-	-	-	7.0 (6.1-7.9)	7.5 (6.6-8.3)	13.0 (11.9-14.2)
SINDI	2007-09	3328	5.4	4.8	10.2	4.7 (4.0-5.3)	4.1 (3.4-4.7)	8.8 (7.9-9.7)
VIP	1992-97	4313	4.8	1.7	6.0	3.8 (3.3-4.4)	1.4 (1.1-1.8)	4.9 (4.4-5.5)
<b>Pooled estimates</b>	<b>NA</b>	<b>46371</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>6.5 (4.2-8.9)</b>	<b>2.6 (1.8-3.4)</b>	<b>9.1 (6.0-12.2)</b>
<i>I</i> <sup>2</sup>						99.3	98.2	99.5

<b>Primary ERM</b>								
BDES	1987-88	4125	-	-	-	4.5 (3.9-5.1)	1.3 (1.0-1.6)	5.8 (5.1-6.5)
Beixinjing	2010-11	3326	0.6	0.6	1.0	0.6 (0.3-0.9)	0.4 (0.2-0.6)	1.0 (0.6-1.3)
HES	2006-07	6196	2.0	0.5	3.0	2.1 (1.6-2.6)	0.4 (0.3-0.6)	3.1 (2.6-3.7)
Jiangning	2012-13	1854	4.6	3.1	7.7	4.3 (3.4-5.2)	3.0 (2.2-3.7)	7.3 (6.1-8.4)
LALES	2000-03	5631	15.6	1.9	17.5	16.1 (15.2-17.1)	2.2 (1.8-2.6)	18.4 (17.3-19.4)
MESA	2002-04	4761	22.7	3.3	26.1	20.2 (19.1-21.3)	2.7 (2.3-3.1)	23.0 (21.7-24.1)
SIMES	2004-06	2734	5.1	4.5	9.5	4.5 (3.7-5.2)	3.8 (3.2-4.5)	8.3 (7.3-9.3)
SINDI	2007-09	2324	3.8	2.7	6.5	4.3 (3.4-5.2)	2.8 (2.1-3.5)	7.0 (5.9-8.2)
<b>Pooled estimates</b>	<b>NA</b>	<b>30951</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>7.1 (3.3-10.8)</b>	<b>2.0 (1.3-2.8)</b>	<b>9.2 (4.7-13.8)</b>
$r^2$						99.6	97.9	99.7
<b>Secondary ERM</b>								
HES	2006-07	269	7.1	3.7	12.3	6.7 (1.9-11.5)	3.7 (0-7.8)	11.1 (5.0-17.3)
Jiangning	2012-13	151	10.6	6.6	17.2	7.0 (3.4-10.7)	3.9 (1.2-6.6)	10.9 (6.6-15.2)
LALES	2000-03	345	27.0	7.5	34.5	19.8 (14.4-25.2)	6.1 (2.9-9.3)	25.9 (20.0-31.9)
MESA	2002-04	1199	34.3	5.8	40.1	25.1 (22.2-28.1)	3.4 (2.5-4.4)	28.6 (25.6-31.6)
SIMES	2004-06	531	9.8	13.6	23.4	5.3 (2.5-8.1)	7.1 (5.2-9.0)	12.4 (9.1-15.7)
SINDI	2007-09	1004	9.1	9.8	18.8	5.1 (3.6-6.5)	6.0 (4.2-7.8)	11.0 (8.8-13.3)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

<b>Pooled estimates</b>	<b>NA</b>	<b>3499</b>	-	-	-	<b>11.4 (4.4-18.5)</b>	<b>5.1 (3.5-6.6)</b>	<b>16.6 (9.7-23.6)</b>
<i>I</i> <sup>2</sup>						97.0	69.4	95.4

ERM, epiretinal membrane; CMR, cellophane macular reflex; PMF, preretinal macular fibrosis; BDES, the Beaver Dam Eye Study; BMES, the Blue Mountains Eye Study; Funagata, the Funagata study; HES, the Handan Eye Study; Hisayama, the Hisayama study; Jiangning, the Jiangning Eye Study; LALES, the Los Angeles Latino Eye Study; MESA, the Multi-Ethnic Study of Atherosclerosis; SiMES, the Singapore Malay Eye Study; SCES, the Singapore Chinese Eye Study; SINDI, the Singapore Indian Eye study; VIP, the Visual Impairment Project.

#: Any ERM: both CMR and PMF. ##: All ERM: both primary and secondary ERM.



**Table 3.** Age-standardised prevalence of epiretinal membranes by subgroups of interest

	CMR			PMF			Any ERM			Reference
	Studies (n)	Prevalence (%; 95%CI)	<i>I</i> <sup>2</sup> (%)	Studies (n)	Prevalence (%; 95%CI)	<i>I</i> <sup>2</sup> (%)	Studies (n)	Prevalence (%; 95%CI)	<i>I</i> <sup>2</sup> (%)	
<b>Race/ethnicity</b>										
Caucasian	4	8.9 (4.6-13.2)	99.4	4	2.0 (1.4-2.7)	88.8	4	11.0 (5.9-16.1)	99.5	2, 6, 7, 10
Asian	8	6.5 (4.6-8.5)	98.2	8	3.6 (2.2-4.9)	98.7	8	10.5 (7.2-13.8)	99.1	3, 4, 5, 8, 9, 10, 19, 20
<b>WHO Regions</b>										
The Americas	3	14.3 (3.6-25.0)	99.8	3	2.4 (1.6-3.2)	91.6	3	14.4 (5.6-23.2)	99.7	2, 10, 11
Western Pacific	9	4.0 (3.1-4.9)	94.2	9	2.7 (1.7-3.7)	98.3	9	8.5 (4.7-8.4)	98.2	3, 4, 5, 6, 7, 8, 9, 19, 20
<b>Testing method</b>										
Photography only	10	7.2 (4.2-10.1)	99.5	10	2.8 (1.9-3.7)	97.8	10	9.1 (6.0-12.2)	99.3	2, 3, 4, 5, 6, 7, 10, 11, 19, 20
Photography + OCT	2	3.4 (1.2-5.5)	94.8	2	1.8 (0-3.7)	97.6	2	5.5 (1.5-9.5)	97.7	8, 9
<b>Photography</b>										
Film	6	5.6 (2.5-8.8)	99.3	6	1.5 (0.9-2.0)	92.2	6	7.0 (3.4-10.7)	99.4	2, 5, 6, 7, 11, 20
Digital	6	7.4 (3.2-11.7)	99.5	6	3.8 (1.9-5.7)	99.0	6	10.0 (5.7-14.3)	99.3	3, 4, 8, 9, 10, 19
<b>Image graded by</b>										
RC at UW–Madison <sup>#</sup>	3	14.3 (3.6-25.0)	99.8	3	2.4 (1.6-3.2)	91.6	3	14.4 (5.6-23.2)	99.7	2, 10, 11
RC at USYD <sup>##</sup>	6	4.4 (3.5-5.4)	92.3	6	3.4 (1.9-4.9)	98.1	6	7.5 (5.1-9.9)	98.1	3, 4, 5, 6, 7, 19
Ophthalmologists or	3	3.0 (1.7-4.2)	90.9	3	2.6 (1.8-3.4)	98.1	3	4.6 (2.3-6.8)	96.4	8, 9, 20



**Table 4.** Pooled odds ratios for risk of any epiretinal membrane

Risk factors	Studies	OR (95%CI)	I <sup>2</sup> (%)	Reference
Age (per year)	5	<b>1.19 (1.13, 1.26)</b>	95.1	3, 4, 5, 9, 10, 19
Sex (female)	6	<b>1.34 (1.17, 1.53)</b>	24.8	3, 4, 5, 9, 19, 20
Myopia (present)	4	1.21 (0.67, 2.19)	88.9	6, 8, 9, 19
Hyperopia (present)	3	1.23 (0.78, 1.94)	83.8	6, 8, 19
Hypertension (present)	6	1.04 (0.90, 1.20)	11.2	4, 5, 6, 9, 19, 20
Diabetes (present)	6	1.13 (0.92, 1.38)	17.1	4, 5, 6, 9, 19, 20
Smoking (present)	7	<b>0.67 (0.58, 0.78)</b>	0	3, 4, 5, 6, 8, 19, 20
Alcohol intake (present)	3	0.97 (0.75, 1.25)	0	6, 9, 20
Early AMD (present)	3	0.96 (0.63, 1.47)	60.7	2, 5, 6
BMI (per kg/m <sup>2</sup> )	5	0.99 (0.98, 1.01)	0	4, 5, 6, 9, 20
Hyperlipidaemia (present)	4	1.05 (0.99, 1.11)	62.0	4, 5, 9, 20


AMD, age-related macular degeneration; BMI, body mass index; OR, odds ratio.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legends:**

**Figure 1.** Flow chart of studies identified, included, and excluded.

For peer review only



Flow chart of studies identified, included, and excluded.

69x77mm (300 x 300 DPI)

# The prevalence and risk factors of epiretinal membranes: a systematic review and meta-analysis of population-based studies

Wei Xiao, Xiaoyun Chen, William Yan, Zhuoting Zhu, Mingguang He

## Literature search strategy

### Terms

1. prevalence, epidemiology, epidemic\*, risk
2. epiretinal membrane\*; erm\*; ierm\*; cellophane macular reflex; preretinal macular fibrosis

### Search strategy

#### PubMed (up to July 11, 2016)

#1	prevalence Fields: Title/Abstract	459388
#2	epidemiology Fields: Title/Abstract	143403
#3	epidemic* Fields: Title/Abstract	80597
#4	risk Fields: Title/Abstract	1507737
#5	#1 OR #2 OR #3 OR #4	1973101
#6	epiretinal membrane* Fields: Title/Abstract	2259
#7	ERM Fields: Title/Abstract	3126
#8	iERM Fields: Title/Abstract	23
#9	cellophane macular reflex Fields: All fields	18
#10	preretinal macular fibrosis Fields: All fields	69
#11	#6 OR #7 OR #8 OR #9 OR #10	4935
#12	#5 AND #11	569

#### Embase (up to July 11, 2016)

#1	prevalence	609473
----	------------	--------

	Fields: ti, ab	
#2	epidemiology Fields: ti, ab	144993
#3	epidemic* Fields: ti, ab	89089
#4	risk Fields: ti, ab	2059117
#5	#1 OR #2 OR #3 OR #4	2622649
#6	epiretinal membrane* Fields: ti, ab	2491
#7	ERM Fields: ti, ab	3555
#8	iERM Fields: ti, ab	22
#9	cellophane macular reflex Fields: All fields	18
#10	preretinal macular fibrosis Fields: All fields	75
#11	#6 OR #7 OR #8 OR #9 OR #10	5570
#12	#5 AND #11	619

### Web of Science (All Databases, 1980 to July 11, 2016)

#### All languages, all document types

#1	TS = prevalence	684438
#2	TS = epidemiology	1440407
#3	TS=epidemic*	100419
#4	TS=risk	2386116
#5	#1 OR #2 OR #3 OR #4	3597103
#6	TS=epiretinal membrane*	3045
#7	TS=ERM	369
#8	TS=iERM	21
#9	TS=cellophane macular reflex	17
#10	TS=preretinal macular fibrosis	67
#11	#6 OR #7 OR #8 OR #9 OR #10	6344
#12	#5 AND #11	956

**Table S1.** Appraisal criteria for study methodology

Quality Criteria	Maximum score
1. Representing the general population	1
2. Appropriately recruiting the population	1
3. Adequate response rate (>70%)	1
4. Objective documentation of the outcomes	1

For peer review only



**Table S2.** Quality score of included studies

Study	Representing the general population	Appropriately recruiting the population	Adequate response rate (>70%)	Objective documentation of the outcomes	Total score
BDES	1	1	1	1	4
Beixinjing	1	1	1	1	4
BMES	1	1	1	1	4
Funagata	1	1	0	1	3
HES	1	1	1	1	4
Hisayama	1	1	0	1	3
Jiangning	1	1	1	1	4
LALES	1	1	1	1	4
MESA	1	1	1	1	4
SCES	1	1	1	1	4
SiMES	1	1	1	1	4
SINDI	1	1	1	1	4
VIP	1	1	1	1	4

# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not available
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6, Suppl. info
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	8

# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10, table2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	table 2-4
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-11, table3
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1, 19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097